{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [],
   "source": [
    "#import packages\n",
    "import pandas as pd \n",
    "from datetime import datetime \n",
    "import json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "#define \n",
    "file_path = r'C:\\Users\\snipt\\OneDrive\\Documents\\fhir\\Alejandro.json'\n",
    "df = pd.read_json(file_path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>resourceType</th>\n",
       "      <th>type</th>\n",
       "      <th>entry</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:f8d8a950-9d1b-06fa-03d4-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:5d7fdd5f-4e6d-d8e5-5ce7-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:459f3302-333c-ef31-eaee-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:e818a68b-4af5-53b6-6861-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:164553f3-2a35-2def-e337-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:8b5e6976-182b-05c9-6c8f-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:1e6bad66-0077-7b19-991c-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:189c5446-0392-3723-b3ec-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:3f2b4ba9-984b-6674-6109-...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:00c55e64-a3cd-b635-a748-...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>264 rows Ã— 3 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    resourceType         type  \\\n",
       "0         Bundle  transaction   \n",
       "1         Bundle  transaction   \n",
       "2         Bundle  transaction   \n",
       "3         Bundle  transaction   \n",
       "4         Bundle  transaction   \n",
       "..           ...          ...   \n",
       "259       Bundle  transaction   \n",
       "260       Bundle  transaction   \n",
       "261       Bundle  transaction   \n",
       "262       Bundle  transaction   \n",
       "263       Bundle  transaction   \n",
       "\n",
       "                                                 entry  \n",
       "0    {'fullUrl': 'urn:uuid:f8d8a950-9d1b-06fa-03d4-...  \n",
       "1    {'fullUrl': 'urn:uuid:5d7fdd5f-4e6d-d8e5-5ce7-...  \n",
       "2    {'fullUrl': 'urn:uuid:459f3302-333c-ef31-eaee-...  \n",
       "3    {'fullUrl': 'urn:uuid:e818a68b-4af5-53b6-6861-...  \n",
       "4    {'fullUrl': 'urn:uuid:164553f3-2a35-2def-e337-...  \n",
       "..                                                 ...  \n",
       "259  {'fullUrl': 'urn:uuid:8b5e6976-182b-05c9-6c8f-...  \n",
       "260  {'fullUrl': 'urn:uuid:1e6bad66-0077-7b19-991c-...  \n",
       "261  {'fullUrl': 'urn:uuid:189c5446-0392-3723-b3ec-...  \n",
       "262  {'fullUrl': 'urn:uuid:3f2b4ba9-984b-6674-6109-...  \n",
       "263  {'fullUrl': 'urn:uuid:00c55e64-a3cd-b635-a748-...  \n",
       "\n",
       "[264 rows x 3 columns]"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Function to extract SNOMED codes from the 'entry' column\n",
    "def extract_snomed_codes_from_entry(entry):\n",
    "    # Accessing the 'resource' field inside the entry\n",
    "    resource = entry.get('resource')\n",
    "\n",
    "    if resource.get('resourceType') == 'Condition':\n",
    "        #print(resource)\n",
    "        #print('Condition resource found')\n",
    "        coding = resource['code'].get('coding', [])\n",
    "        #print(coding)\n",
    "        \n",
    "        # Extract SNOMED codes and display text\n",
    "        conditions = [item['display'] for item in coding]\n",
    "        condition_string = ' '.join(conditions)\n",
    "\n",
    "        return condition_string\n",
    "    \n",
    "    return []\n",
    "\n",
    "def extract_gender(entry): \n",
    "    #access gender \n",
    "    resource = entry.get('resource')\n",
    "    \n",
    "    if resource.get('resourceType') == 'Patient':\n",
    "        \n",
    "        gender = resource.get('gender')\n",
    "        \n",
    "        return gender\n",
    "\n",
    "def extract_birth_date(entry): \n",
    "    #access birth date \n",
    "    resource = entry.get('resource')\n",
    "    \n",
    "    if resource.get('resourceType') == 'Patient':\n",
    "        \n",
    "        gender = resource.get('birthDate')\n",
    "        \n",
    "        return gender\n",
    "    \n",
    "def extract_diagnosis_date(entry):\n",
    "    resource = entry.get('resource', {})\n",
    "    \n",
    "    if resource.get('resourceType') == 'Condition':\n",
    "        onset_datetime = resource.get('onsetDateTime')\n",
    "\n",
    "        if onset_datetime:\n",
    "            # Parse the date or slice to get YYYY-MM-DD\n",
    "            try:\n",
    "                onset_date = datetime.fromisoformat(onset_datetime).date()\n",
    "                return str(onset_date)\n",
    "            except ValueError:\n",
    "                return onset_datetime[:10]  # Fallback for malformed dates\n",
    "    \n",
    "    return None\n",
    "\n",
    "def extract_name(entry):\n",
    "     #access name \n",
    "    resource = entry.get('resource')\n",
    "    \n",
    "    if resource.get('resourceType') == 'Patient':\n",
    "\n",
    "        name = resource.get('name')\n",
    "        official_name = name[0]['given']\n",
    "        name_string = ' '.join(official_name)\n",
    "        \n",
    "        return name_string\n",
    "\n",
    "# Apply the extraction function to each row in the DataFrame\n",
    "patient_df = df \n",
    "patient_df['name'] = df['entry'].apply(extract_name).fillna(method='ffill')\n",
    "patient_df['sex'] = df['entry'].apply(extract_gender).fillna(method='ffill')\n",
    "patient_df['diagnosis_date'] = df['entry'].apply(extract_diagnosis_date)\n",
    "patient_df['birth_date'] = df['entry'].apply(extract_birth_date).fillna(method='ffill')\n",
    "patient_df['conditions'] = df['entry'].apply(extract_snomed_codes_from_entry)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>resourceType</th>\n",
       "      <th>type</th>\n",
       "      <th>entry</th>\n",
       "      <th>name</th>\n",
       "      <th>sex</th>\n",
       "      <th>diagnosis_date</th>\n",
       "      <th>birth_date</th>\n",
       "      <th>conditions</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2014-03-19</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute viral pharyngitis (disorder)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2018-12-04</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Viral sinusitis (disorder)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-15</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute bacterial sinusitis (disorder)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Sputum finding (finding)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Fever (finding)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Loss of taste (finding)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Suspected COVID-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>COVID-19</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    resourceType         type  \\\n",
       "58        Bundle  transaction   \n",
       "202       Bundle  transaction   \n",
       "219       Bundle  transaction   \n",
       "223       Bundle  transaction   \n",
       "224       Bundle  transaction   \n",
       "225       Bundle  transaction   \n",
       "226       Bundle  transaction   \n",
       "227       Bundle  transaction   \n",
       "\n",
       "                                                 entry          name   sex  \\\n",
       "58   {'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...  Alejandro916  male   \n",
       "202  {'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...  Alejandro916  male   \n",
       "219  {'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...  Alejandro916  male   \n",
       "223  {'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...  Alejandro916  male   \n",
       "224  {'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...  Alejandro916  male   \n",
       "225  {'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...  Alejandro916  male   \n",
       "226  {'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...  Alejandro916  male   \n",
       "227  {'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...  Alejandro916  male   \n",
       "\n",
       "    diagnosis_date  birth_date                            conditions  \n",
       "58      2014-03-19  2001-01-13    Acute viral pharyngitis (disorder)  \n",
       "202     2018-12-04  2001-01-13            Viral sinusitis (disorder)  \n",
       "219     2020-02-15  2001-01-13  Acute bacterial sinusitis (disorder)  \n",
       "223     2020-02-23  2001-01-13              Sputum finding (finding)  \n",
       "224     2020-02-23  2001-01-13                       Fever (finding)  \n",
       "225     2020-02-23  2001-01-13               Loss of taste (finding)  \n",
       "226     2020-02-23  2001-01-13                    Suspected COVID-19  \n",
       "227     2020-02-23  2001-01-13                              COVID-19  "
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Display the updated DataFrame with SNOMED codes\n",
    "patient_df = patient_df[patient_df['conditions'].apply(lambda x: bool(x))]\n",
    "patient_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\snipt\\AppData\\Local\\Temp\\ipykernel_25404\\4241226509.py:2: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  patient_df['birth_date'] = pd.to_datetime(patient_df['birth_date'])\n",
      "C:\\Users\\snipt\\AppData\\Local\\Temp\\ipykernel_25404\\4241226509.py:3: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  patient_df['diagnosis_date'] = pd.to_datetime(patient_df['diagnosis_date'])\n",
      "C:\\Users\\snipt\\AppData\\Local\\Temp\\ipykernel_25404\\4241226509.py:4: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  patient_df['age_at_diagnosis'] = (patient_df['diagnosis_date'] - patient_df['birth_date']).dt.days // 365\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>resourceType</th>\n",
       "      <th>type</th>\n",
       "      <th>entry</th>\n",
       "      <th>name</th>\n",
       "      <th>sex</th>\n",
       "      <th>diagnosis_date</th>\n",
       "      <th>birth_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>age_at_diagnosis</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2014-03-19</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute viral pharyngitis (disorder)</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2018-12-04</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Viral sinusitis (disorder)</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-15</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute bacterial sinusitis (disorder)</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Sputum finding (finding)</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Fever (finding)</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Loss of taste (finding)</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Suspected COVID-19</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    resourceType         type  \\\n",
       "58        Bundle  transaction   \n",
       "202       Bundle  transaction   \n",
       "219       Bundle  transaction   \n",
       "223       Bundle  transaction   \n",
       "224       Bundle  transaction   \n",
       "225       Bundle  transaction   \n",
       "226       Bundle  transaction   \n",
       "227       Bundle  transaction   \n",
       "\n",
       "                                                 entry          name   sex  \\\n",
       "58   {'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...  Alejandro916  male   \n",
       "202  {'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...  Alejandro916  male   \n",
       "219  {'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...  Alejandro916  male   \n",
       "223  {'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...  Alejandro916  male   \n",
       "224  {'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...  Alejandro916  male   \n",
       "225  {'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...  Alejandro916  male   \n",
       "226  {'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...  Alejandro916  male   \n",
       "227  {'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...  Alejandro916  male   \n",
       "\n",
       "    diagnosis_date birth_date                            conditions  \\\n",
       "58      2014-03-19 2001-01-13    Acute viral pharyngitis (disorder)   \n",
       "202     2018-12-04 2001-01-13            Viral sinusitis (disorder)   \n",
       "219     2020-02-15 2001-01-13  Acute bacterial sinusitis (disorder)   \n",
       "223     2020-02-23 2001-01-13              Sputum finding (finding)   \n",
       "224     2020-02-23 2001-01-13                       Fever (finding)   \n",
       "225     2020-02-23 2001-01-13               Loss of taste (finding)   \n",
       "226     2020-02-23 2001-01-13                    Suspected COVID-19   \n",
       "227     2020-02-23 2001-01-13                              COVID-19   \n",
       "\n",
       "     age_at_diagnosis  \n",
       "58                 13  \n",
       "202                17  \n",
       "219                19  \n",
       "223                19  \n",
       "224                19  \n",
       "225                19  \n",
       "226                19  \n",
       "227                19  "
      ]
     },
     "execution_count": 66,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#back calculate the age\n",
    "patient_df['birth_date'] = pd.to_datetime(patient_df['birth_date'])\n",
    "patient_df['diagnosis_date'] = pd.to_datetime(patient_df['diagnosis_date'])\n",
    "patient_df['age_at_diagnosis'] = (patient_df['diagnosis_date'] - patient_df['birth_date']).dt.days // 365\n",
    "patient_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "C:\\Users\\snipt\\AppData\\Local\\Temp\\ipykernel_25404\\3583738640.py:7: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame.\n",
      "Try using .loc[row_indexer,col_indexer] = value instead\n",
      "\n",
      "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  patient_df['clean_conditions'] = patient_df['conditions'].apply(remove_parentheses)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>resourceType</th>\n",
       "      <th>type</th>\n",
       "      <th>entry</th>\n",
       "      <th>name</th>\n",
       "      <th>sex</th>\n",
       "      <th>diagnosis_date</th>\n",
       "      <th>birth_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>age_at_diagnosis</th>\n",
       "      <th>clean_conditions</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2014-03-19</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute viral pharyngitis (disorder)</td>\n",
       "      <td>13</td>\n",
       "      <td>Acute viral pharyngitis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2018-12-04</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Viral sinusitis (disorder)</td>\n",
       "      <td>17</td>\n",
       "      <td>Viral sinusitis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-15</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Acute bacterial sinusitis (disorder)</td>\n",
       "      <td>19</td>\n",
       "      <td>Acute bacterial sinusitis</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Sputum finding (finding)</td>\n",
       "      <td>19</td>\n",
       "      <td>Sputum finding</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Fever (finding)</td>\n",
       "      <td>19</td>\n",
       "      <td>Fever</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Loss of taste (finding)</td>\n",
       "      <td>19</td>\n",
       "      <td>Loss of taste</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>Suspected COVID-19</td>\n",
       "      <td>19</td>\n",
       "      <td>Suspected COVID-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>Bundle</td>\n",
       "      <td>transaction</td>\n",
       "      <td>{'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...</td>\n",
       "      <td>Alejandro916</td>\n",
       "      <td>male</td>\n",
       "      <td>2020-02-23</td>\n",
       "      <td>2001-01-13</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>19</td>\n",
       "      <td>COVID-19</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    resourceType         type  \\\n",
       "58        Bundle  transaction   \n",
       "202       Bundle  transaction   \n",
       "219       Bundle  transaction   \n",
       "223       Bundle  transaction   \n",
       "224       Bundle  transaction   \n",
       "225       Bundle  transaction   \n",
       "226       Bundle  transaction   \n",
       "227       Bundle  transaction   \n",
       "\n",
       "                                                 entry          name   sex  \\\n",
       "58   {'fullUrl': 'urn:uuid:f70501c9-6ce3-49a8-6b5b-...  Alejandro916  male   \n",
       "202  {'fullUrl': 'urn:uuid:55f14c53-154a-70ef-4cb9-...  Alejandro916  male   \n",
       "219  {'fullUrl': 'urn:uuid:d26e44ca-27a1-11bb-4ff2-...  Alejandro916  male   \n",
       "223  {'fullUrl': 'urn:uuid:b4d9cdca-6379-1c01-aa28-...  Alejandro916  male   \n",
       "224  {'fullUrl': 'urn:uuid:798b678c-ba57-1dac-f6cc-...  Alejandro916  male   \n",
       "225  {'fullUrl': 'urn:uuid:21eaebfe-995e-c462-ab16-...  Alejandro916  male   \n",
       "226  {'fullUrl': 'urn:uuid:1507922d-912b-7712-ce48-...  Alejandro916  male   \n",
       "227  {'fullUrl': 'urn:uuid:d912349e-c5d1-26cb-0b4f-...  Alejandro916  male   \n",
       "\n",
       "    diagnosis_date birth_date                            conditions  \\\n",
       "58      2014-03-19 2001-01-13    Acute viral pharyngitis (disorder)   \n",
       "202     2018-12-04 2001-01-13            Viral sinusitis (disorder)   \n",
       "219     2020-02-15 2001-01-13  Acute bacterial sinusitis (disorder)   \n",
       "223     2020-02-23 2001-01-13              Sputum finding (finding)   \n",
       "224     2020-02-23 2001-01-13                       Fever (finding)   \n",
       "225     2020-02-23 2001-01-13               Loss of taste (finding)   \n",
       "226     2020-02-23 2001-01-13                    Suspected COVID-19   \n",
       "227     2020-02-23 2001-01-13                              COVID-19   \n",
       "\n",
       "     age_at_diagnosis            clean_conditions  \n",
       "58                 13    Acute viral pharyngitis   \n",
       "202                17            Viral sinusitis   \n",
       "219                19  Acute bacterial sinusitis   \n",
       "223                19             Sputum finding   \n",
       "224                19                      Fever   \n",
       "225                19              Loss of taste   \n",
       "226                19          Suspected COVID-19  \n",
       "227                19                    COVID-19  "
      ]
     },
     "execution_count": 67,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import re \n",
    "\n",
    "def remove_parentheses(text):\n",
    "    return re.sub(r'\\(.*?\\)', '', text)\n",
    "\n",
    "# Apply the function to the 'conditions' column\n",
    "patient_df['clean_conditions'] = patient_df['conditions'].apply(remove_parentheses)\n",
    "patient_df\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2014-03-19 00:00:00, Condition: Acute viral pharyngitis (disorder), Age at Diagnosis: 13\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2018-12-04 00:00:00, Condition: Viral sinusitis (disorder), Age at Diagnosis: 17\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-15 00:00:00, Condition: Acute bacterial sinusitis (disorder), Age at Diagnosis: 19\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-23 00:00:00, Condition: Sputum finding (finding), Age at Diagnosis: 19\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-23 00:00:00, Condition: Fever (finding), Age at Diagnosis: 19\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-23 00:00:00, Condition: Loss of taste (finding), Age at Diagnosis: 19\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-23 00:00:00, Condition: Suspected COVID-19, Age at Diagnosis: 19\n",
      "Patient Name: Alejandro916, Sex: male, Diagnosis Date: 2020-02-23 00:00:00, Condition: COVID-19, Age at Diagnosis: 19\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Convert the relevant patientnt columns into a string for each row\n",
    "patient_summary = \"\"\n",
    "\n",
    "# Iterate over each row in the DataFrame\n",
    "for index, row in patient_df.iterrows():\n",
    "    patient_string = (\n",
    "        f\"Patient Name: {row['name']}, \"\n",
    "        f\"Sex: {row['sex']}, \"\n",
    "        f\"Diagnosis Date: {row['diagnosis_date']}, \"\n",
    "        f\"Condition: {row['conditions']}, \"\n",
    "        f\"Age at Diagnosis: {row['age_at_diagnosis']}\\n\"\n",
    "    )\n",
    "    # Append the patient string to the overall summary\n",
    "    patient_summary += patient_string\n",
    "\n",
    "# After the loop, patient_summary contains all patient strings combined\n",
    "print(patient_summary)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Acute viral pharyngitis  OR Viral sinusitis  OR Acute bacterial sinusitis  OR Sputum finding  OR Fever  OR Loss of taste  OR Suspected COVID-19 OR COVID-19\n"
     ]
    }
   ],
   "source": [
    "# Extract the 'conditions' column and combine them into a single string\n",
    "conditions_str = ' OR '.join(patient_df['clean_conditions'].values)\n",
    "\n",
    "# Output the combined conditions string\n",
    "print(conditions_str)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "metadata": {},
   "outputs": [],
   "source": [
    "import requests\n",
    "import json \n",
    "from pandas import json_normalize"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Success: {'studies': [{'protocolSection': {'identificationModule': {'nctId': 'NCT06684431', 'orgStudyIdInfo': {'id': 'CCHF-NP-1'}, 'organization': {'fullName': 'Karolinska Institutet', 'class': 'OTHER'}, 'briefTitle': 'Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever', 'officialTitle': 'A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever', 'acronym': 'CCHF-NP-1'}, 'statusModule': {'statusVerifiedDate': '2024-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-11-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-11-11', 'studyFirstSubmitQcDate': '2024-11-11', 'studyFirstPostDateStruct': {'date': '2024-11-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-11-14', 'lastUpdatePostDateStruct': {'date': '2024-11-18', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Matti SÃ¤llberg', 'investigatorTitle': 'Director of Department of Laboratory Medicine', 'investigatorAffiliation': 'Karolinska Institutet'}, 'leadSponsor': {'name': 'Karolinska Institutet', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.', 'detailedDescription': 'This First-in-human dose-escalation vaccine phase I study aims to evaluate safety and reactogenicity of the investigational vaccine N-pVAX1, against Crimean Congo Hemorrhagic Fever, delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.\\n\\nThe study vaccine dose is planned to be staggered, starting with the low-dose group (0.45 mg), followed by the mid-dose group (0.9 mg), and finally the high-dose group (1.8 mg). In total 15 healthy volunteers at the ages of 18-60 will be enrolled.\\n\\nPrimary objective:\\n\\nâ€¢ The primary objective of this study is to assess the safety and reactogenicity of the investigational vaccine N-pVAX1 delivered by in vivo EP given as three im doses at weeks 0, 4 and 12.\\n\\nThe secondary objectives:\\n\\nâ€¢ To investigate the humoral immune response to the investigational vaccine administered as three doses, by measuring CCHF nucleocapsid antibody levels.\\n\\nExploratory objective:\\n\\nâ€¢ To investigate in more detail the humoral response and to analyze the cellular immune response to the investigational vaccine.\\n\\nTrial participants will be followed-up for local and systemic adverse reactions throughout the study period. Blood samples to measure presence of antibody levels to the vaccine components and cellular immunity will be taken at Day 14 and 28 post first and second vaccine dose and at Day 14 and 3 months post last vaccine dose.'}, 'conditionsModule': {'conditions': ['Crimean Congo Hemorrhagic Fever'], 'keywords': ['N-pVAX1', 'Phase I', 'Dose-escalation']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Dose-escalation: first low-dose group (n=5), then mid-dose group (n=5), last high-dose group (n=5)', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 15, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Vaccine', 'type': 'EXPERIMENTAL', 'description': 'N-pVAX1 vaccine', 'interventionNames': ['Biological: N-pVAX1']}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'N-pVAX1', 'description': 'Crimean Congo Hemorrhagic Fever Vaccine', 'armGroupLabels': ['Vaccine']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Local reactions', 'description': 'Local reactions (pain at the injection site, redness, and swelling) for up to 7 days after each vaccine dose.', 'timeFrame': 'For up to 7 days after each vaccine dose'}, {'measure': 'Visual analogue scale (VAS) score', 'description': 'Visual analogue scale (VAS) score to rate the level of pain experienced immediately (0 minutes), and after 5, 15, 30 and 60 minutes post-EP.', 'timeFrame': 'At vaccination (0 minutes), and after 5, 15, 30 and 60 minutes post-EP'}, {'measure': 'Systemic events', 'description': 'Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) for 7 days after each vaccine dose.', 'timeFrame': 'For 7 days after each vaccine dose'}, {'measure': 'Unsolicited AEs', 'description': 'Unsolicited AEs from the first study dose to 28 days after the last vaccination.', 'timeFrame': 'From the first study dose to 28 days after the last vaccination'}, {'measure': 'Serious Adverse Events (SAEs)/suspected unexpected serious adverse reactions (SUSARs)', 'description': 'Serious Adverse Events (SAEs)/suspected unexpected serious adverse reactions (SUSARs) from the first study dose until the study end at 3 months after last vaccination.', 'timeFrame': 'From the first study dose until the study end at 3 months after last vaccination'}], 'secondaryOutcomes': [{'measure': 'Change in antibody levels to the CCHF nucleocapsid protein', 'description': 'Change from baseline sample (a two-fold increase in endpoint titer or a 50% increase in optical density at a 1:62, 1:125, 1:250, 1:500, or 1:1000 serum dilution) in antibody levels to the CCHF nucleocapsid protein by inhouse and/or commercial assays during the study period.', 'timeFrame': 'At Baseline, day 14 and 28 post vaccine dose and at 3 months post last vaccine dose'}], 'otherOutcomes': [{'measure': 'Exploratory: Description of in depth humoral and cellular immunological responses', 'description': 'Description of in depth humoral and cellular immunological responses after receiving investigational vaccine at each sampling.', 'timeFrame': 'At Baseline, day 14 and 28 post vaccine dose and at 3 months post last vaccine dose'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\n1. Men and women between the ages of 18 and 60 years (at the time of consent).\\n2. Healthy participant, according to the investigator's clinical judgment, as established by medical history, vital signs, physical examination, and laboratory assessments.\\n3. No clinically significant laboratory abnormalities as determined by the investigator at screening.\\n\\n   Note: one retest of lab tests is allowed within the screening window.\\n4. Negative HIV 1/2 antibody/antigen test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody at screening.\\n5. Participant with a body mass index (BMI) 20-30.0 kg/m2.\\n6. Provide written informed consent before initiation of any study procedures.\\n7. A female participant is eligible for this study if she is one of the following:\\n\\n   * of non-childbearing potential (i.e., women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses in greater than or equal to 1 year)\\n   * of childbearing potential but agrees to practice highly effective contraception or abstinence (if this is the preferred and usual lifestyle of the participant) from 30 days prior to vaccination up to 3 months after last vaccination.\\n\\n   Highly effective methods of contraception include one or more of the following:\\n   1. male partner who is sterile (vasectomised) prior to the female study subject's entry into the study and is the sole sexual partner for the female subject;\\n   2. hormonal (oral, intravaginal, transdermal, implantable or injectable)\\n   3. an intrauterine hormone-releasing system (IUS)\\n   4. an intrauterine device (IUD) with a documented failure rate of \\\\< 1%.\\n8. A female participant is eligible if she is willing to abstain from donating oocyte and a male participant if he is willing to abstain from donating sperm from the screening visit up to 3 months after last vaccination.\\n9. A male participant who is sexually active is eligible if he is willing to use a condom from the screening visit up to 3 months after last vaccination except if the male participant is sterile (e.g. vasectomised); the unique female sexual partner is postmenopausal, is permanently sterilized (e.g. hysterectomy or tubal ligation), or use a highly effective method of contraception.\\n10. Able to understand and comply with planned study procedures and willing to be available for all study-required procedures, visits and calls for the duration of the study.\\n\\nExclusion Criteria:\\n\\n1. History of presence of pulmonary disorders (chronic obstructive pulmonary lung disease etc) or asthma (exception of allergic asthma, which is allowed).\\n2. History or presence of thrombocytopenia and/or bleeding disorders.\\n3. A positive serum pregnancy test at screening or urine pregnancy test prior to study injection, women who are planning to become pregnant during the study, or women who are breastfeeding.\\n4. Clinically relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory, autoimmune, central nervous system or neurological diseases.\\n5. Use of immunosuppressive drugs as e.g. corticosteroids (excluding topical preparations and inhalers) within 3 months prior to vaccination or 6 months for chemotherapies and all along the study.\\n6. Vaccination within 2 weeks prior to vaccination or planning to receive a licensed vaccine before month 3 (e.g. inactivated influenza vaccine).\\n7. History of severe adverse reactions to vaccine administration, including anaphylaxis and related symptoms, such as urticaria, respiratory difficulty, angioedema and abdominal pain to vaccines, or history of known or suspected allergic reaction likely to be exacerbated by any component of the Investigational vaccine.\\n8. Participation in another investigational clinical study within four weeks before the screening visit or planned before the study completion.\\n9. Subjects with confirmed or suspected immunodeficiency.\\n10. Any condition that in the opinion of the principal investigator (PI) would jeopardize the safety or rights of a person participating in the trial or would render the person unable to comply with the protocol.\", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '60 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Soo Aleman, MD, PhD', 'role': 'CONTACT', 'phone': '+46812381913', 'email': 'soo.aleman@regionstockohlm.se'}], 'overallOfficials': [{'name': 'Soo Aleman, MD, PhD', 'affiliation': 'Karolinska University Hospital', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Phase I Unit, Karolinska University Hospital', 'status': 'RECRUITING', 'city': 'Stockholm', 'zip': '17176', 'country': 'Sweden', 'contacts': [{'name': 'Soo Aleman, MD, PhD', 'role': 'CONTACT', 'email': 'soo.aleman@regionstockholm.se'}], 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006482', 'term': 'Hemorrhagic Fevers, Viral'}, {'id': 'D006479', 'term': 'Hemorrhagic Fever, Crimean'}, {'id': 'D005334', 'term': 'Fever'}], 'ancestors': [{'id': 'D001832', 'term': 'Body Temperature Changes'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D001102', 'term': 'Arbovirus Infections'}, {'id': 'D000079426', 'term': 'Vector Borne Diseases'}, {'id': 'D017282', 'term': 'Tick-Borne Diseases'}, {'id': 'D002044', 'term': 'Bunyaviridae Infections'}], 'browseLeaves': [{'id': 'M8464', 'name': 'Fever', 'asFound': 'Fever', 'relevance': 'HIGH'}, {'id': 'M9568', 'name': 'Hemorrhagic Fevers, Viral', 'asFound': 'Hemorrhagic Fever', 'relevance': 'HIGH'}, {'id': 'M9565', 'name': 'Hemorrhagic Fever, Crimean', 'asFound': 'Crimean-Congo Hemorrhagic Fever', 'relevance': 'HIGH'}, {'id': 'M2454', 'name': 'Hyperthermia', 'relevance': 'LOW'}, {'id': 'M5111', 'name': 'Body Temperature Changes', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M4412', 'name': 'Arbovirus Infections', 'relevance': 'LOW'}, {'id': 'M2054', 'name': 'Vector Borne Diseases', 'relevance': 'LOW'}, {'id': 'M19577', 'name': 'Tick-Borne Diseases', 'relevance': 'LOW'}, {'id': 'T5864', 'name': 'Viral Hemorrhagic Fever', 'asFound': 'Hemorrhagic Fever', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360', 'name': 'Vaccines', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05735782', 'orgStudyIdInfo': {'id': 'PICTO-COVID-SECUELAS-00015'}, 'organization': {'fullName': 'Arturo Jauretche National University', 'class': 'OTHER'}, 'briefTitle': 'Clinical and Biological Characterization of Post COVID-19 Syndrome', 'officialTitle': 'Association of Symptoms, Clinical and Biochemical Characteristics in Post COVID-19 Syndrome: a Case-control Study'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-02-16', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-04-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-02-16', 'studyFirstSubmitQcDate': '2023-02-16', 'studyFirstPostDateStruct': {'date': '2023-02-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-17', 'lastUpdatePostDateStruct': {'date': '2023-02-21', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Laura Antonietti', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': 'Arturo Jauretche National University'}, 'leadSponsor': {'name': 'Arturo Jauretche National University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Hospital El Cruce', 'class': 'OTHER'}, {'name': 'National University of Cuyo', 'class': 'OTHER'}, {'name': 'Universidad Nacional de La Plata', 'class': 'OTHER'}, {'name': 'University of Buenos Aires', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this observational study is to describe the symptoms that persist for more than 12 weeks after the acute episode in participants who had COVID-19, and compare the functional, socioeconomic and occupational effects with a post-COVID-19 control group without persistent symptoms after the COVID-19 acute event.\\n\\nThe main questions it aims to answer are:\\n\\n* What are the characteristics of symptoms that persist for more than 12 weeks in participants who have had COVID19 in the last year?\\n* What are the health-related quality of life and psychosocial effects in participants with persistent symptoms of COVID-19, compared to a post-COVID-19 control group without persistent symptoms after the acute episode of COVID-19?', 'detailedDescription': 'Two groups of cases and one group of controls will be included. A group of cases with persistent respiratory and/or cardiovascular symptoms (cardiorespiratory cases), and another group with persistent non-cardiorespiratory symptoms.\\n\\nParticipants who report at least two symptoms of intensity greater than or equal to severe will be classified as non-cardiorespiratory cases.\\n\\nControls will be participants with a history of confirmed SARS-CoV-2 infection, but without current or past persistent symptoms (ie, who resolved their symptoms during the acute episode or whose symptoms did not persist more than 4 weeks after onset).\\n\\nControls will be matched to cases by sex, age (with a margin of up to Â±5 years), and time since diagnosis of the COVID-19 episode considered as the origin of post-COVID-19 symptoms in the cases (with a margin of of Â±30 days).\\n\\nThe visit will include the application of the questionnaires for the evaluation of symptoms and quality of life associated with health, the clinical evaluation and the extraction of a blood sample.\\n\\nThe extraction of a blood sample will allow biochemical determinations, the complete blood count and vitamin D level to be carried out. Subsequently, an aliquot will be reserved for mechanistic evaluation (inflammatory markers, immunological and microRNA studies).'}, 'conditionsModule': {'conditions': ['Long COVID'], 'keywords': ['Post-Acute COVID-19 Syndrome', 'Long COVID', 'Post-COVID Conditions', 'Post Acute COVID-19 Syndrome']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood'}, 'enrollmentInfo': {'count': 75, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Case-Control', 'description': 'Case group: Participants with persistent symptoms post-COVID-19 more than12 weeks after COVID-19 acute infection Control group: Participants without persistent symptoms after a COVID-19 acute infection.', 'interventionNames': ['Diagnostic Test: Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome', 'Diagnostic Test: Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome']}], 'interventions': [{'type': 'DIAGNOSTIC_TEST', 'name': 'Clinical, mental health and psychosocial profile of Post-COVID-19 syndrome', 'description': 'Evaluation of persistent symptoms of COVID-19 and its association with psychological, cognitive and social status in comparison to a healthy control group', 'armGroupLabels': ['Case-Control']}, {'type': 'DIAGNOSTIC_TEST', 'name': 'Diagnostic performance of echocardiographic and biological markers in Post-COVID-19 syndrome', 'description': 'Determine the inflammatory, immune profile and ventricular function in post-COVID-19 participants compared to a control group', 'armGroupLabels': ['Case-Control']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Psychosocial, Cognitive and Health-related Quality Of Life association with symptoms Post COVID-19 syndrome', 'description': 'Assessment of symptoms and health-related quality of life (ISARIC), fatigue (Chalder fatigue scale and SPHERE questionnaire) and psychosocial evaluation(PHQ-9 and GAD-7 questionnaires)', 'timeFrame': 'More than 12 weeks post- acute COVID-19 episode'}], 'secondaryOutcomes': [{'measure': 'IL-6, Anti-SARS-Cov-2 S-RBD IgG Antibodies and vitamin D levels', 'description': 'Evaluate inflammatory, immune and vitamin D profile in post-COVID-19', 'timeFrame': 'More than 12 weeks post- acute COVID-19 episode'}], 'otherOutcomes': [{'measure': 'Circulating miRNA expression', 'description': 'RNA-Seq in plasma of participants with persistent symptoms of COVID-19 and comparison', 'timeFrame': 'More than 12 weeks post- acute COVID-19 episode'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Two groups of cases and one group of controls will be included. A group of cases with persistent respiratory and/or cardiovascular symptoms (cardiorespiratory cases), and another group with persistent non-cardiorespiratory symptoms. For participation in the study, people who meet the following inclusion criteria and none of the exclusion criteria will be considered.\\n\\nInclusion Criteria:\\n\\n* Age equal to or greater than 18 years;\\n* Documented SARS-CoV-2 infection by PCR or antigen test;\\n* Ability to understand the objectives of the study;\\n* Acceptance to participate in the study and willingness to sign the informed consent.\\n* Permanent residence in Buenos Aires Metropolitan Area.\\n\\nExclusion Criteria:\\n\\n* Women who report being pregnant, who are in the puerperium or lactation period at the time of the evaluation.\\n* People with known chronic debilitating conditions, defined as:\\n\\n  i. heart failure, ii. symptomatic Coronary Heart Disease, iii. Diagnosis of cancer in the last 5 years iv. symptomatic anemia, v. chronic obstructive pulmonary disease or greater than moderate asthma, vi. heart valve disease more than mild, vii. cognitive impairment prior to the diagnosis of COVID-19, viii. diagnosis of schizophrenia or depression, ix. any other condition that, at the discretion of the treating professional or the research team, may explain or justify the aforementioned symptoms.\\n* Participants who are undergoing an acute pathology or who have undergone it in the last 4 weeks. In this case, they may be contacted again, after the period of time considered acceptable by the treating professional or the research team to invite them to participate.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'Adults living in Buenos Aires with history of COVID-19', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Laura Antonietti, MD, MHA', 'role': 'CONTACT', 'phone': '+541158544004', 'email': 'laurayantonietti@gmail.com'}, {'name': 'Javier Mariani, MD', 'role': 'CONTACT', 'email': 'ja_mariani@hotmail.com'}], 'overallOfficials': [{'name': 'Laura Antonietti, MD, MHA', 'affiliation': 'Arturo Jauretche National University', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Javier Mariani, MD', 'affiliation': 'Hospital El Cruce', 'role': 'STUDY_CHAIR'}, {'name': 'Walter Manucha, PhD', 'affiliation': 'National University of Cuyo', 'role': 'STUDY_CHAIR'}, {'name': 'Mariela Paz, PhD', 'affiliation': 'University of Buenos Aires', 'role': 'STUDY_CHAIR'}, {'name': 'MartÃ­n Rumbo, PhD', 'affiliation': 'Universidad Nacional de La Plata', 'role': 'STUDY_CHAIR'}, {'name': 'Liliana Dain, PhD', 'affiliation': 'University of Buenos Aires', 'role': 'STUDY_CHAIR'}, {'name': 'Carlos Tajer', 'affiliation': 'Hospital El Cruce', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Hospital El Cruce', 'status': 'RECRUITING', 'city': 'Florencio Varela', 'state': 'Buenos Aires', 'zip': '1888', 'country': 'Argentina', 'contacts': [{'name': 'Laura Y Antonietti, MD, MHA', 'role': 'CONTACT', 'phone': '01158544004', 'email': 'laurayantonietti@gmail.com'}, {'name': 'Javier Mariani, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': -34.82722, 'lon': -58.39556}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D000094024', 'term': 'Post-Acute COVID-19 Syndrome'}, {'id': 'D013577', 'term': 'Syndrome'}], 'ancestors': [{'id': 'D004194', 'term': 'Disease'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D000094025', 'term': 'Post-Infectious Disorders'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}], 'browseLeaves': [{'id': 'M16355', 'name': 'Syndrome', 'asFound': 'Syndrome', 'relevance': 'HIGH'}, {'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M3013', 'name': 'Post-Acute COVID-19 Syndrome', 'asFound': 'Long COVID', 'relevance': 'HIGH'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'M3014', 'name': 'Post-Infectious Disorders', 'relevance': 'LOW'}, {'id': 'M6147', 'name': 'Chronic Disease', 'relevance': 'LOW'}, {'id': 'M22700', 'name': 'Disease Attributes', 'relevance': 'LOW'}, {'id': 'T170', 'name': 'Acute Graft Versus Host Disease', 'relevance': 'LOW'}, {'id': 'T1303', 'name': 'Chronic Graft Versus Host Disease', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05505682', 'orgStudyIdInfo': {'id': 'IRB024'}, 'organization': {'fullName': 'National Environment Agency, Singapore', 'class': 'OTHER_GOV'}, 'briefTitle': 'Impact of Project Wolbachia - Singapore on Dengue Incidence', 'officialTitle': 'Assessing the Efficacy of Male Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Singapore: a Cluster Randomized Controlled Trial'}, 'statusModule': {'statusVerifiedDate': '2023-11', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-07-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-07-19', 'studyFirstSubmitQcDate': '2022-08-16', 'studyFirstPostDateStruct': {'date': '2022-08-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-13', 'lastUpdatePostDateStruct': {'date': '2023-11-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Lee Ching Ng', 'investigatorTitle': 'Group Director (Environmental Health Institute)', 'investigatorAffiliation': 'National Environment Agency, Singapore'}, 'leadSponsor': {'name': 'National Environment Agency, Singapore', 'class': 'OTHER_GOV'}, 'collaborators': [{'name': 'Ministry of Health, Singapore', 'class': 'OTHER_GOV'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The study is a cluster-randomised controlled trial set in Singapore, to assess if the deployment of male Wolbachia-infected Aedes aegypti mosquitoes can reduce dengue incidence in intervention clusters.', 'detailedDescription': 'The study is designed as a parallel, two-arm, non-blinded cluster-randomised controlled trial to be conducted in high-rise public housing estates in Singapore. The aim is to determine whether large-scale deployment of male Wolbachia-infected Ae. aegypti mosquitoes can significantly reduce dengue incidence in intervention clusters. The investigators will use the cluster-randomised design, with the study area comprising 15 clusters with a total area of 10.9 km2, covering approximately 722,000 residents in 1,700 apartment blocks. Eight clusters will be randomly selected to receive the intervention, while the other seven will serve as non-intervention clusters. Intervention efficacy will be estimated through two primary endpoints: (1) odds ratio of Wolbachia exposure distribution (i.e. probability of living in an intervention cluster) among laboratory-confirmed reported dengue cases compared to test-negative controls, and (2) laboratory-confirmed reported dengue counts normalized by population size in intervention versus non-intervention clusters.'}, 'conditionsModule': {'conditions': ['Dengue']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Parallel, two-arm, non-blinded cluster-randomised controlled trial', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention clusters', 'type': 'EXPERIMENTAL', 'description': 'Residential areas that receive releases of male Wolbachia-infected Aedes aegypti', 'interventionNames': ['Biological: Biological (Male Wolbachia-infected Aedes aegypti)']}, {'label': 'Non-intervention clusters', 'type': 'NO_INTERVENTION', 'description': 'Residential areas that do not receive releases of male Wolbachia-infected Aedes aegypti'}], 'interventions': [{'type': 'BIOLOGICAL', 'name': 'Biological (Male Wolbachia-infected Aedes aegypti)', 'description': 'Releases of male Wolbachia-infected Aedes aegypti mosquitoes', 'armGroupLabels': ['Intervention clusters']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Odds ratio of Wolbachia exposure distribution among laboratory-confirmed reported dengue cases compared to test-negative controls', 'description': 'Dengue cases and dengue test-negative controls data will be obtained from the national surveillance network of diagnostic laboratories which receive samples for dengue testing.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Laboratory-confirmed reported dengue case counts normalized by population size in intervention versus non-intervention clusters', 'description': 'Dengue cases data will be obtained from the national surveillance network of diagnostic laboratories which receive samples for dengue testing.', 'timeFrame': 'Up to 3 years'}], 'secondaryOutcomes': [{'measure': 'Prevalence of Ae. aegypti/Ae. albopictus mosquitoes', 'description': 'Data will be obtained from the national gravitrap surveillance system', 'timeFrame': 'Up to 3 years'}, {'measure': 'Public Attitudes, Perceptions & Knowledge (APK) of Wolbachia and other vector control interventions', 'description': 'Sentiment surveys pre-trial and during the course of the trial, using true/false and Likert-type scales. Higher scores mean better outcomes.', 'timeFrame': 'Up to 3 years'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion criteria:\\n\\n* Dengue-suspected patients living in the intervention and non-intervention clusters whose blood samples are collected by a national network of diagnostic laboratories that support private clinics, public polyclinics, or public/private hospitals.\\n* Test positive cases: Patients with virologically confirmed DENV infection through RT-qPCR, testing positive for NS1 antigen or IgM. A positive test for any of the three assays would classify the patient as a dengue case.\\n* Test negative controls: Patients with negative test results for DENV through RT-qPCR, NS1 antigen ELISA, or DENV IgM.', 'healthyVolunteers': False, 'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lee Ching Ng, PhD', 'role': 'CONTACT', 'phone': '+65 67719108', 'email': 'NG_Lee_Ching@nea.gov.sg'}], 'overallOfficials': [{'name': 'Lee Ching Ng, PhD', 'affiliation': 'Group Director (Environmental Health Institute)', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'National Environment Agency', 'status': 'RECRUITING', 'city': 'Singapore', 'country': 'Singapore', 'contacts': [{'name': 'Lee Ching Ng, PhD', 'role': 'CONTACT', 'email': 'NG_Lee_Ching@nea.gov.sg'}], 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}]}, 'referencesModule': {'references': [{'pmid': '29855331', 'type': 'BACKGROUND', 'citation': \"Anders KL, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Andari B, Jewell NP, Rances E, O'Neill SL, Simmons CP, Utarini A. The AWED trial (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected mosquito deployments to reduce dengue incidence in Yogyakarta, Indonesia: study protocol for a cluster randomised controlled trial. Trials. 2018 May 31;19(1):302. doi: 10.1186/s13063-018-2670-z.\"}, {'pmid': '34107180', 'type': 'BACKGROUND', 'citation': \"Utarini A, Indriani C, Ahmad RA, Tantowijoyo W, Arguni E, Ansari MR, Supriyati E, Wardana DS, Meitika Y, Ernesia I, Nurhayati I, Prabowo E, Andari B, Green BR, Hodgson L, Cutcher Z, Rances E, Ryan PA, O'Neill SL, Dufault SM, Tanamas SK, Jewell NP, Anders KL, Simmons CP; AWED Study Group. Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue. N Engl J Med. 2021 Jun 10;384(23):2177-2186. doi: 10.1056/NEJMoa2030243.\"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003715', 'term': 'Dengue'}], 'ancestors': [{'id': 'D000096724', 'term': 'Mosquito-Borne Diseases'}, {'id': 'D000079426', 'term': 'Vector Borne Diseases'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D001102', 'term': 'Arbovirus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018177', 'term': 'Flavivirus Infections'}, {'id': 'D018178', 'term': 'Flaviviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D006482', 'term': 'Hemorrhagic Fevers, Viral'}], 'browseLeaves': [{'id': 'M6913', 'name': 'Dengue', 'asFound': 'Dengue', 'relevance': 'HIGH'}, {'id': 'M3255', 'name': 'Mosquito-Borne Diseases', 'relevance': 'LOW'}, {'id': 'M2054', 'name': 'Vector Borne Diseases', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M4412', 'name': 'Arbovirus Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20323', 'name': 'Flavivirus Infections', 'relevance': 'LOW'}, {'id': 'M20324', 'name': 'Flaviviridae Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M8464', 'name': 'Fever', 'relevance': 'LOW'}, {'id': 'M9568', 'name': 'Hemorrhagic Fevers, Viral', 'relevance': 'LOW'}, {'id': 'M2454', 'name': 'Hyperthermia', 'relevance': 'LOW'}, {'id': 'T1794', 'name': 'Dengue Fever', 'asFound': 'Dengue', 'relevance': 'HIGH'}, {'id': 'T5864', 'name': 'Viral Hemorrhagic Fever', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05787431', 'orgStudyIdInfo': {'id': '1454/11-01-2023'}, 'organization': {'fullName': 'National and Kapodistrian University of Athens', 'class': 'OTHER'}, 'briefTitle': 'Levels of Physical Activity After SARS-CoV-2 Infection in Pre-illness Vaccinated and Unvaccinated Greek Adults.', 'officialTitle': 'Levels of Physical Activity After SARS-CoV-2 Infection in Greek Adults: the Role of Pre-illness Vaccination and the Number of Reinfections.'}, 'statusModule': {'statusVerifiedDate': '2023-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-02-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-05-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-07-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-03-21', 'studyFirstSubmitQcDate': '2023-03-21', 'studyFirstPostDateStruct': {'date': '2023-03-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-03-21', 'lastUpdatePostDateStruct': {'date': '2023-03-28', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Emmanouil D. Zacharakis', 'investigatorTitle': 'Emmanouil D. Zacharakis, emzach@phed.uoa.gr, +306977915982', 'investigatorAffiliation': 'National and Kapodistrian University of Athens'}, 'leadSponsor': {'name': 'Emmanouil D. Zacharakis', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': \"Coronavirus infection has an impact on several aspects of everyday life including the levels of Physical Activity (PA). Investigators wish to (1) detect changes on PA levels in recovered SARS-CoV-2 (COVID-19) adults compared to the pre-infection levels and (2) identify a potential relationship between changes of PA levels and pre-illness vaccination profile along with individual's number of infection/reinfections. It is assumed that the impact of COVID-19 infection on PA would be more pronounced in cases of repeated infections and/or in the unvaccinated compared to the vaccinated individuals against COVID-19.\", 'detailedDescription': \"Coronavirus identified in 2019, SARS-CoV-2 (COVID-19), has caused a pandemic of respiratory illness in which manifestation ranging from asymptomatic presentation to critically illness with severe pneumonia, acute respiratory distress syndrome, respiratory failure, or multiple organ failure. It may influence several aspects of everyday life including the levels of Physical Activity such as walking, cycling, sports or active recreation and, thus, has negative effect on general health and quality of life. Recent findings demonstrate a relation between COVID-19 infection and impairment in functional capacity, and suggest that may also be associated with an increased risk of acute and post-acute death. Moreover, individuals who have been infected might suffer long-term consequences as a result of their infection (Long COVID), for few weeks (short term) or 10-20 weeks (medium term) or more than six months (long term) post-infection.\\n\\nThe current study is designed to assess changes in PA (overall and in four domains i.e. daily occupation, transportation to and from daily occupation, leisure time activities, and regular sporting activities) caused by COVID-19 infection (i.e. in the short term, 4 weeks post infection) concerning the pre-illness vaccination profile and the number of infections/reinfections using a web-based validated questionnaire in a large population of Greece. Investigators hypothesize that the impact of COVID-19 infection on PA levels would be more pronounced in cases of repeated infections and/or in the unvaccinated compared to the vaccinated individuals against COVID-19. With regard to the potential burden of COVID-19 in functional capacity, investigators wish:\\n\\n1. to detect changes on PA levels in recovered COVID-19 adults compared to the pre-infection levels as a result of a post-effect impact;\\n2. to identify a potential relationship between changes of PA levels and pre-illness vaccination profile along with individual's number of infection/reinfections so as to detect correlations amongst different parameters.\\n\\nThe Greek version of the revised Active-Q (AQGR) which is a self-reported, online, interactive physical activity questionnaire that assesses adult's habitual activity on weekly basis (in four main PA domains: daily occupation, transportation to and from daily occupation, leisure time activities, and regular sporting activities) is employed. Regarding questions of medical treatment during COVID-19 infection, individual's number of infection/reinfections and other relative parameters, additional questionnaire items have been incorporated. In total, the current web-based questionnaire consisted of 60-67 questions, based on previous responses and follow-up patterns, and will be extensively used to address the aims of the current study.\"}, 'conditionsModule': {'conditions': ['COVID-19 (Coronavirus Disease 2019)'], 'keywords': ['Physical Activity, exercise, public health, Post COVID']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Unvaccinated individuals', 'description': 'COVID-19 recovered individuals who are not been vaccinated with any dose of COVID-19 vaccines.'}, {'label': 'Vaccinated individuals', 'description': 'COVID-19 recovered individuals who are vaccinated with one or more dose of COVID-19 vaccines, and stratified by sub-groups.'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Levels of Physical Activity (PA)', 'description': 'Levels of PA, before and after COVID-19 infection, will be recorded', 'timeFrame': 'One (1) month at least after recovery from COVID-19 infection'}], 'otherOutcomes': [{'measure': 'Protective effect of vaccination in post-COVID-19 burden on Physical Activity (PA)', 'description': 'Correlations between the number of doses of vaccines and the post-COVID-19 burden on PA will be performed', 'timeFrame': 'One (1) month at least after recovery from COVID-19 infection'}, {'measure': 'The role of the number of re-infections and post-COVID-19 burden on PA', 'description': 'Correlations between the number of re-infections and the post-COVID-19 burden on PA will be performed', 'timeFrame': 'One (1) month at least after recovery from the last COVID-19 infection'}]}, 'eligibilityModule': {'eligibilityCriteria': \"Inclusion Criteria:\\n\\nCOVID-19 recovered individuals aged from 18 to 80 years old.\\n\\nExclusion Criteria:\\n\\nIndividuals without any confirmed COVID-19 infection, severe musculoskeletal problems, cognitive impairment/dementia, participation in any strict weight loss control program, gestation or childbirth within one year of the study's start date.\", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'studyPopulation': 'COVID-19 recovered individuals aged from 18 to 80 years old who are residents of Greece and have been diagnostically confirmed with COVID-19 infection and recovered at least one month before answering the survey instrument.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Emmanouil D. Zacharakis, PhD', 'role': 'CONTACT', 'phone': '(+30)', 'email': 'emzach@phed.uoa.gr'}, {'name': 'Panteleimon Bakirtzoglou, PhD', 'role': 'CONTACT', 'phone': '(+30) 6972207967', 'email': 'bakirtzoglou@phed.auth.gr'}], 'overallOfficials': [{'name': 'Emmanouil D. Zacharakis, PhD', 'affiliation': 'National and Kapodistrian University of Athens', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'National and Kapodistrian University of Athens', 'status': 'RECRUITING', 'city': 'Athens', 'state': 'Attica', 'zip': '17237', 'country': 'Greece', 'contacts': [{'name': 'Emmanuil D. Zacharakis, PhD', 'role': 'CONTACT', 'email': 'emzach@phed.uoa.gr'}, {'name': 'Panteleimon Bakirtzoglou, PhD', 'role': 'CONTACT', 'email': 'bakirtzoglou@phed.auth.gr'}, {'name': 'Dimitrios I. Bourdas, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Antonios K. Travlos, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Panteleimon Bakritzoglou, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Vasileios Andrianopoulos, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Emmanouil D. Zacharakis, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.97945, 'lon': 23.71622}}]}, 'referencesModule': {'references': [{'pmid': '33096721', 'type': 'RESULT', 'citation': 'Bourdas DI, Zacharakis ED. Impact of COVID-19 Lockdown on Physical Activity in a Sample of Greek Adults. Sports (Basel). 2020 Oct 21;8(10):139. doi: 10.3390/sports8100139.'}, {'pmid': '34664028', 'type': 'RESULT', 'citation': 'Bourdas DI, Zacharakis ED, Travlos AK, Souglis A, Georgali TI, Gofas DC, Ktistakis IE, Deltsidou A. Impact of lockdown on smoking and sleeping in the early COVID-19 presence: Datasets of Greek Adults sample. Data Brief. 2021 Dec;39:107480. doi: 10.1016/j.dib.2021.107480. Epub 2021 Oct 14.'}, {'pmid': '32934972', 'type': 'RESULT', 'citation': 'Bourdas DI, Zacharakis ED. Evolution of changes in physical activity over lockdown time: Physical activity datasets of four independent adult sample groups corresponding to each of the last four of the six COVID-19 lockdown weeks in Greece. Data Brief. 2020 Oct;32:106301. doi: 10.1016/j.dib.2020.106301. Epub 2020 Sep 11.'}, {'pmid': '34204988', 'type': 'RESULT', 'citation': 'Bourdas DI, Zacharakis ED, Travlos AK, Souglis A. Return to Basketball Play Following COVID-19 Lockdown. Sports (Basel). 2021 Jun 3;9(6):81. doi: 10.3390/sports9060081.'}], 'seeAlsoLinks': [{'label': 'Official web-page of the study', 'url': 'https://hub.uoa.gr/the-impact-of-the-disease-and-re-infections-of-covid-19-on-physical-activity-in-a-vaccinated-and-non-vaccinated-population-in-greece/'}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D007239', 'term': 'Infections'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19 (Coronavirus Disease 2019)', 'relevance': 'HIGH'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M2435', 'name': 'Reinfection', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360', 'name': 'Vaccines', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05808231', 'orgStudyIdInfo': {'id': 'Pharm-202005.12'}, 'organization': {'fullName': 'Universitas Padjadjaran', 'class': 'OTHER'}, 'briefTitle': 'Effectiveness and Safety of Quinine Sulfate as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia ( DEAL-COVID19 )', 'officialTitle': 'An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults', 'acronym': 'DEAL-COVID19'}, 'statusModule': {'statusVerifiedDate': '2023-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-04-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-30', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2023-05-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-04-10', 'studyFirstSubmitQcDate': '2023-04-10', 'studyFirstPostDateStruct': {'date': '2023-04-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-04-10', 'lastUpdatePostDateStruct': {'date': '2023-04-11', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Keri Lestari', 'investigatorTitle': 'Prof. Dr. Keri Lestari, M.Si, S.Si, Apt.', 'investigatorAffiliation': 'Universitas Padjadjaran'}, 'leadSponsor': {'name': 'Universitas Padjadjaran', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Research and Innovation Agency of Indonesia', 'class': 'UNKNOWN'}, {'name': 'Prodia Diacro Laboratories P.T.', 'class': 'INDUSTRY'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of Quinine Sulfate as an add-on therapy in hospitalized adults with COVID-19.\\n\\nThe study is a multi-center trial that will be conducted in up to approximately 2 sites nationally. New sites may be added as needed after appropriate assessment. Interim monitoring will be conducted to evaluate the arms and for safety and effectiveness. Any changes would be accompanied by an updated sample size.\\n\\nSubjects will be assessed while hospitalized. All subjects will undergo a series of laboratory tests (CBC, SGOT, SGPT, Ureum, Creatinine, EKG, and PCR), clinical examination (clinical assessment, vital signs, accompanying drugs, and other medical conditions) and safety assessment (serious adverse events/ SAE)\\n\\nRandomization will be performed 1:1 for each arm. Arm 1 = Standard of Care (SoC) alone, arm 2 = SoC + Quinine Sulfate', 'detailedDescription': \"This is an adaptive, multicenter, randomized, open-label, controlled trial to evaluate the effectiveness and safety of quinine sulfate in mild to moderate COVID-19 hospitalized adults with confirmed positive Rapid Test or PCR.\\n\\nThe study is a multi-center trial that will be conducted in up to approximately 2 sites nationally. New sites may be added as needed after appropriate assessment. Interim monitoring will be conducted to evaluate the arms and for effectiveness and safety. Any change would be accompanied by an updated sample size.\\n\\nEligible patients are male and female patients aged â‰¥ 18 years to \\\\< 60 years old who are hospitalized with Covid-19 based on clinical symptoms determined by physician and confirmed by Rapid Test or PCR test with mild to moderate symptoms that fulfill the inclusion and exclusion criteria stated in the protocol. Total Subjects: 100\\n\\nSubjects with any of these conditions will be excluded:\\n\\n* Received quinine sulfate, hydroxychloroquine, chloroquine, lumefantrine, or mefloquine within 30 days prior to this research;\\n* Having receive any treatment for COVID-19 prior to this research;\\n* Any contraindication to quinine sulfate\\n* Inability to swallow pills or any other reason that compliance with the medical regimen is not likely;\\n* Pregnant and breastfeeding;\\n* Severe underlying disease where treatment and follow up is not likely to be beneficial to the patient based on physician judgement (e.g. retinopathy, cardiovascular disease (QTc \\\\> 500 mdet (narrow QRS); QTc â‰¥ 550 mdet (wide QRS)), heart arrythmia, uncontrolled diabetes mellitus, hypertension, chronic pulmonary disease, asthma, chronic kidney disease (Creatinine \\\\> 2x normal value), liver disease (SGOT/SGPT \\\\> 2x normal value), chronic neurological disease, or etc.). This includes people requiring care in designated supported living facilities and severe dementia;\\n* Platelet count less than 150,000 and more than 450,000 cells/Î¼L;\\n* Possibility of being transferred to a non-study-hospital within 72 hours.\\n\\nAny suspected serious adverse event reaction is reported to CRO/Sponsor and EC within 24 hours, using patient's study ID.\\n\\nDuring the study conduct, the study team shall keep all the relevant source documents and transcribe the data in case report form (CRF). The study team should also update study essential document (e.g. subject log, investigational product accountability log, etc.) and keep the copy captured by scan/camera for monitoring/audit/inspection purpose.\\n\\nThe study is expected to be finished in 1,5 years.\\n\\nStandard of Care (SoC) treatment is based on COVID-19 Treatment Protocol (4th edition, 2020) published by Medical Associations (PDPI, PERKI, PAPDI,PERDATIN, IDAI).\\n\\nMILD CASE:\\n\\nArm 1 = SoC alone Arm 2 = SoC + Quinine Sulfate (2 tablets of Quinine Sulfate 200 mg administered orally once daily for 5 days).\\n\\nMODERATE CASE:\\n\\nArm 1 = SoC alone Arm 2 = SoC + Quinine Sulfate (2 tablets of Quinine Sulfate 200 mg administered orally every 12 hours in Day 1, followed with 2 tablets of Quinine Sulfate 200 mg administered once daily for 5-7 days).\\n\\nIt is anticipated that patients with COVID-19 will present to participating hospitals, and that no external recruitment efforts towards potential subjects are needed. Recruitment efforts may also include dissemination of information about this trial to other medical professionals/hospitals.\\n\\nThe Ethics Committee will approve the recruitment process and all materials prior to any recruitment to prospective subjects directly.\\n\\nScreening will begin with a brief discussion with study staff. Some will be excluded based on demographic data and medical history (i.e., pregnant, \\\\< 18 years of age, renal failure, etc.). Information about the study will be presented to potential subjects (or legally authorized representative) and questions will be asked to determine potential eligibility. Screening procedures can begin only after informed consent is obtained.\\n\\nTo evaluate the effectiveness of Quinine Sulfate in the therapy of mild to moderate hospitalized adults with confirmed COVID-19 based on subject's clinical condition assessed using a 7-point ordinal scale. Secondary parameters will be Incidence and duration of Oxygenation (days of oxygenation), incidence is defined as number of days from randomization until the subject received oxygenation, duration is defined as total days of the use of oxygenation; incidence of Ventilation (days to receiving ventilation) and length of stay in hospital (after subject received randomization code until subject discharge/death/recovered).\\n\\nTo evaluate the safety of quinine sulfate on laboratory parameters, serious adverse events and QT interval based on ECG result.\\n\\n* Change in CBC, SGOT, SGPT, Ureum and Creatinine;\\n* Number of reported Serious Adverse Event (SAE);\\n* Change in QT interval based on ECG result.\\n\\nAnalyses relate outcome to the randomly allocated treatment (e.g. intent-to-treat). The primary analyses assess any effects of treatment allocation on all-cause in-hospital mortality, analyzing separately people who already at mild and moderate level at entry and those who did not. Interim analysis will be carried out after 50% subject enrolled. A Data Safety Monitoring Board (DSMB) will monitor ongoing results to ensure subject well-being and safety as well as study integrity. The DSMB will evaluate the study safety parameter after 50% subject enrolled in the study.\\n\\nThe main secondary analyses assess any effects of treatment allocation on:\\n\\n* Duration of hospitalization (time from randomization to discharge) (days);\\n* Incidence and duration of Oxygenation;\\n* Incidence and duration of Ventilation;\\n* Clinical outcome from baseline at day 10 or if discharged earlier\\n\\nStudy related data will be recorded in electronically. All the data in the source documents shall be collected by the study team to be transcribed in the electronic case report form (eCRF) and other study documents are stored in the electronic trial master file (eTMF). Once the document recorded, the electronic data will be automatically available for monitoring/audit/inspection purpose. All the electronic system used and data recording in the study must be conducted in compliance to Good Clinical Practice.\\n\\nThe investigator must assure that subjects' anonymity will be maintained and that their identities are protected from unauthorized parties. On CRFs or other documents submitted to the funder, subjects should not be identified by their names, but by an identification code. The investigator should keep a subject enrolment log showing codes, names and addresses. The investigator should maintain documents not for submission to funder, e.g. subjects' written consent forms, in strict confidence.\\n\\nThe investigator shall ensure the quality control and quality assurance of the data generated during the study and how the data will be handled, including providing access to monitoring activities, audit and inspection and source documents which will be used in the study. Investigator will permit monitoring, audits and inspections by funder/CRO, EC, and regulatory bodies.\\n\\nAll source records including electronic data (if any) will be stored in secured systems in accordance with institutional policies and locally applicable regulation. All the essential documents should be retained until at least 5 years after the study ended or based on the applicable regulatory requirements or based on the agreement with the funder.\\n\\nThe Drug Safety Monitoring Board (DSMB) is an Independent Data Monitoring Committee consisting of doctors who are experienced in clinical trials, statisticians, and other members who do not direct involvement with this study. The DSMB responsible for the ongoing review of a clinical trial and for making recommendations to the sponsor concerning the continuation, modification, and termination of the trial as it is being conducted. The DSMB will be the only committee that is allowed to review the confidential data in the study. The statistician will analyze the subject's security data and report to DSMB to be evaluated more closely. The key responsibilities of the DSMB are to ensure patient safety by routine review of overall safety data including all SAEs, SUSARs, all severe AEs and AEs leading to drug or study discontinuation and, where applicable, literature cases and information from Competent Authorities(CAs) and by judging the relevance of the events for patients' safety. The DSMB will review the results of data that has been analyzed in accordance with SAP and consider other evidence arising from other studies and will provide advice to the Trial Steering Committee (TSC) (the research committee and national coordinator) regarding the sustainability of this study. The DSMB may recommend the TSC to the recruitment or study termination or provide recommendations related to alternatives treatment (if any)\"}, 'conditionsModule': {'conditions': ['COVID-19'], 'keywords': ['COVID-19', 'Quinine Sulfate']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants will be randomised to be in Arm 1 or Arm 2 using pre-defined randomisation list; 1:1 for each arm.\\n\\nArm 1 receives Standard of Care Arm 2 receives Standard of Care+Quinine Sulfate', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Control Group', 'type': 'OTHER', 'description': 'Standard of Care alone', 'interventionNames': ['Drug: Standard of Care']}, {'label': 'Experimental Group', 'type': 'OTHER', 'description': 'Standard of Care + Quinine Sulfate', 'interventionNames': ['Drug: Standard of Care + Quinine Sulfate']}], 'interventions': [{'type': 'DRUG', 'name': 'Standard of Care + Quinine Sulfate', 'description': 'Standard of Care + Quinine Sulfate', 'armGroupLabels': ['Experimental Group']}, {'type': 'DRUG', 'name': 'Standard of Care', 'description': 'Standard of Care for COVID-19 mild and moderate symptom', 'armGroupLabels': ['Control Group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The clinical condition of the subjects assessed on a 7-point ordinal scale', 'description': 'The clinical condition of the subjects was assessed until day 10 using a 7-point ordinal scale, as follows:\\n\\n1. Death\\n2. Hospitalization, with invasive mechanical ventilation or ECMO\\n3. Hospitalization, with non-invasive ventilation or high-flow oxygen device;\\n4. Hospitalized, requires additional oxygen;\\n5. Hospitalized, does not require additional oxygen;\\n6. Not hospitalized, activity restrictions;\\n7. No hospitalization, no activity restrictions', 'timeFrame': 'From the date of randomization until the date of first documented subject discharge or death from any cause, assessed up to 10 days'}], 'secondaryOutcomes': [{'measure': 'Duration of oxygenation', 'description': 'Total days of oxygen supplementation', 'timeFrame': 'From the date of randomization until the date of first documented subject discharge or death from anycause, assessed up to 10 days'}, {'measure': 'Duration of ventilation', 'description': 'Total days of receiving ventilation', 'timeFrame': 'From the date of randomization until the date of first documented subject discharge or death from anycause, assessed up to 10 days'}, {'measure': 'Length of stay', 'description': 'Total days the subjects were hospitalized', 'timeFrame': 'From the date of randomization until the date of first documented subject discharge or death from anycause, assessed up to 10 days'}], 'otherOutcomes': [{'measure': 'Safety Outcome (Change in CBC, SGOT, SGPT, Ureum and Creatinine)', 'description': 'Change in CBC, SGOT, SGPT, Ureum and Creatinine on the day before treatment and at the end of treatment/on discharge from the hospital', 'timeFrame': 'Will be examined at days 0 (before treatment) and at the end of treatment'}, {'measure': 'Safety Outcome (Number of reported Serious Adverse Event)', 'description': 'Number of reported Serious Adverse Event', 'timeFrame': 'From the date of randomization until the date of first documented subject discharge or death from anycause, assessed up to 10 days'}, {'measure': 'Safety Outcome (Change in QT interval based on ECG result)', 'description': 'Change in QT interval based on ECG results measured on days 0, 3, 6 and 9 after starting treatment', 'timeFrame': 'Will be examined at days 0, 3, 6, 9 after starting treatment'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Male and female patients aged â‰¥ 18 years to 50 years old who are hospitalized with Covid-19 based on clinical symptoms determined by physician and confirmed by Rapid Test or PCR test with mild to moderate symptoms\\n* Female subjects of child-bearing age agree to take effective contraceptive measures during the study until seven days of the last oral medication\\n* Willing to receive a random assignment to any designated treatment group and not participating in another study at the same time\\n* Not participating in other research at the same time.\\n* Subjects agreed to participate in the study and signed an information sheet and informed consent.\\n\\nExclusion Criteria:\\n\\n* Received quinine sulfate, hydroxychloroquine, chloroquine, lumefantrine, or mefloquine within 30 days prior to this research;\\n* Having receive any treatment for COVID-19 prior to this research;\\n* Any contraindication to quinine sulfate\\n* Inability to swallow pills or any other reason that compliance with the medical regimen is not likely;\\n* Pregnant and breastfeeding;\\n* Severe underlying disease where treatment and follow up is not likely to be beneficial to the patient based on physician judgement (e.g. retinopathy, cardiovascular disease (QTc \\\\> 500 mdet (narrow QRS); QTc â‰¥ 550 mdet (wide QRS)), heart arrythmia, uncontrolled diabetes mellitus, hypertension, chronic pulmonary disease, asthma, chronic kidney disease (Creatinine \\\\> 2x normal value), liver disease (SGOT/SGPT \\\\> 2x normal value), chronic neurological disease, or etc.). This includes people requiring care in designated supported living facilities and severe dementia;\\n* Platelet count less than 150,000 and more than 450,000 cells/Î¼L;\\n* Possibility of being transferred to a non-study-hospital within 72 hours.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '50 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Keri Lestari', 'role': 'CONTACT', 'phone': '+62811216942', 'email': 'lestarikd@unpad.ac.id'}], 'locations': [{'facility': 'Gatot Soebroto Army Central Hospital (RSPAD)', 'status': 'RECRUITING', 'city': 'Jakarta', 'state': 'DKI Jakarta', 'zip': '10410', 'country': 'Indonesia', 'contacts': [{'name': 'Dewiyana Andari Kusmana', 'role': 'CONTACT'}], 'geoPoint': {'lat': -6.21462, 'lon': 106.84513}}, {'facility': 'Dr. Hasan Sadikin Central General Hospital (RSHS)', 'status': 'RECRUITING', 'city': 'Bandung', 'state': 'West Java', 'zip': '40161', 'country': 'Indonesia', 'contacts': [{'name': 'Iceu Dimas Kulsum', 'role': 'CONTACT'}], 'geoPoint': {'lat': -6.92222, 'lon': 107.60694}}]}, 'referencesModule': {'references': [{'pmid': '32450107', 'type': 'RESULT', 'citation': 'Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 May 22:S0140-6736(20)31180-6. doi: 10.1016/S0140-6736(20)31180-6. Online ahead of print. Erratum In: Lancet. 2020 May 30:S0140-6736(20)31249-6. doi: 10.1016/S0140-6736(20)31249-6.'}, {'pmid': '32020029', 'type': 'RESULT', 'citation': 'Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4. No abstract available.'}, {'pmid': '32074550', 'type': 'RESULT', 'citation': 'Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.'}, {'pmid': '32145363', 'type': 'RESULT', 'citation': 'Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Apr;55(4):105932. doi: 10.1016/j.ijantimicag.2020.105932. Epub 2020 Mar 4. No abstract available.'}, {'pmid': '32070753', 'type': 'RESULT', 'citation': 'Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15. No abstract available.'}, {'pmid': '31996494', 'type': 'RESULT', 'citation': 'Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020 Mar 16;14(1):69-71. doi: 10.5582/bst.2020.01020. Epub 2020 Jan 28.'}, {'pmid': '26953343', 'type': 'RESULT', 'citation': 'Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, Huang F, Peng T, Zhang J, Liu C, Tao L, Zhang H. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). J Biol Chem. 2016 Apr 22;291(17):9218-32. doi: 10.1074/jbc.M116.716100. Epub 2016 Mar 7.'}, {'pmid': '26246395', 'type': 'RESULT', 'citation': 'Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.'}, {'pmid': '32194981', 'type': 'RESULT', 'citation': 'Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020. No abstract available.'}, {'pmid': '32196083', 'type': 'RESULT', 'citation': 'Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020 Jul 1;75(7):1667-1670. doi: 10.1093/jac/dkaa114.'}, {'pmid': '32205204', 'type': 'RESULT', 'citation': 'Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.'}, {'pmid': '32391667', 'type': 'RESULT', 'citation': 'Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H. [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03. Chinese.'}, {'type': 'RESULT', 'citation': 'Lestari K, Sitorus T, Instiaty, et al. (last). Molecular docking of quinine, chloroquine and hydroxychroloquine to angiotensin converting enzyme 2 (ACE2) for discovering new potential COVID-19 antidote. J Adv Pharm Edu Res. 2020;10(2):1-4.'}, {'pmid': '29940786', 'type': 'RESULT', 'citation': 'Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, Coppes RP, Engedal N, Mari M, Reggiori F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435-1455. doi: 10.1080/15548627.2018.1474314. Epub 2018 Jul 20.'}, {'pmid': '16640347', 'type': 'RESULT', 'citation': 'Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, De Clercq E. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem. 2006 May 4;49(9):2845-9. doi: 10.1021/jm0601856.'}, {'pmid': '16956382', 'type': 'RESULT', 'citation': \"Bray PG, Mungthin M, Hastings IM, Biagini GA, Saidu DK, Lakshmanan V, Johnson DJ, Hughes RH, Stocks PA, O'Neill PM, Fidock DA, Warhurst DC, Ward SA. PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol. 2006 Oct;62(1):238-51. doi: 10.1111/j.1365-2958.2006.05368.x. Epub 2006 Aug 31.\"}, {'pmid': '29257067', 'type': 'RESULT', 'citation': 'Nqoro X, Tobeka N, Aderibigbe BA. Quinoline-Based Hybrid Compounds with Antimalarial Activity. Molecules. 2017 Dec 19;22(12):2268. doi: 10.3390/molecules22122268.'}, {'pmid': '12435804', 'type': 'RESULT', 'citation': 'Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, Coley AM, Foley M, Haystead TA. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol. 2002 Dec;62(6):1364-72. doi: 10.1124/mol.62.6.1364.'}, {'pmid': '15078100', 'type': 'RESULT', 'citation': 'Kwiek JJ, Haystead TA, Rudolph J. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry. 2004 Apr 20;43(15):4538-47. doi: 10.1021/bi035923w.'}, {'pmid': '28169590', 'type': 'RESULT', 'citation': 'Gachelin G, Garner P, Ferroni E, Trohler U, Chalmers I. Evaluating Cinchona bark and quinine for treating and preventing malaria. J R Soc Med. 2017 Feb;110(2):73-82. doi: 10.1177/0141076816688411. No abstract available.'}, {'type': 'RESULT', 'citation': 'Winstanley, P. Handbook of drugs for tropical parasitic infections. 2nd Edition. Transactions of the Royal Society of Tropical Medicine and Hygiene; 1996.'}, {'type': 'RESULT', 'citation': 'GroÃŸe M, Ruetalo N, Businger R, Rheber S, Setz C, Auth J, et al. Evidence That Quinine Exhibits Antiviral Activity against SARS-CoV-2 Infection In Vitro. 2020;14.'}, {'type': 'RESULT', 'citation': 'Burhan E, Susanto A, Nasution S, Ginanjar E, Pitoyo C, Susilo A, et al. COVID-19 PROTOCOL. 1st ed. Jakarta: Association of Indonesian Pulmonary Doctors (PDPI); 2020.'}, {'type': 'RESULT', 'citation': 'BPOM. Information on Drugs for COVID-19 in Indonesia'}, {'type': 'RESULT', 'citation': 'WHO. Public health emerging solidarity trial: World Health Organization COVID-19 Core Protocol. 2020.'}, {'pmid': '8134732', 'type': 'RESULT', 'citation': 'Whitehead J. Sample size calculations for ordered categorical data. Stat Med. 1993 Dec 30;12(24):2257-71. doi: 10.1002/sim.4780122404. Erratum In: Stat Med 1994 Apr 30;13(8):871.'}], 'seeAlsoLinks': [{'label': 'Infeksi Emerging: Media Informasi Resmi Terkini Penyakit Infeksi Emerging.', 'url': 'https://infeksiemerging.kemkes.go.id/'}, {'label': \"WHO Director-General's opening remarks at the media briefing on COVID-19\", 'url': 'https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---03-june-2020'}, {'label': 'National Library of Medicine', 'url': 'https://clinicaltrials.gov/'}, {'label': 'FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate)', 'url': 'https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-new-risk-management-plan-and-patient-medication-guide-qualaquin/'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011803', 'term': 'Quinine'}], 'ancestors': [{'id': 'D000962', 'term': 'Antimalarials'}, {'id': 'D000981', 'term': 'Antiprotozoal Agents'}, {'id': 'D000977', 'term': 'Antiparasitic Agents'}, {'id': 'D000890', 'term': 'Anti-Infective Agents'}, {'id': 'D009125', 'term': 'Muscle Relaxants, Central'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}, {'id': 'D009465', 'term': 'Neuromuscular Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D018712', 'term': 'Analgesics, Non-Narcotic'}, {'id': 'D000700', 'term': 'Analgesics'}, {'id': 'D018689', 'term': 'Sensory System Agents'}], 'browseLeaves': [{'id': 'M14653', 'name': 'Quinine', 'asFound': 'Non-resectable', 'relevance': 'HIGH'}, {'id': 'M4280', 'name': 'Antimalarials', 'relevance': 'LOW'}, {'id': 'M4298', 'name': 'Antiprotozoal Agents', 'relevance': 'LOW'}, {'id': 'M4294', 'name': 'Antiparasitic Agents', 'relevance': 'LOW'}, {'id': 'M4214', 'name': 'Anti-Infective Agents', 'relevance': 'LOW'}, {'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}, {'id': 'M20786', 'name': 'Analgesics, Non-Narcotic', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}, {'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'MuRelCen', 'name': 'Muscle Relaxants, Central'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT03842982', 'orgStudyIdInfo': {'id': 'CHIPPI-1808'}, 'secondaryIdInfos': [{'id': '2018-003680-62', 'type': 'EUDRACT_NUMBER'}], 'organization': {'fullName': 'Centre Oscar Lambret', 'class': 'OTHER'}, 'briefTitle': 'Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)', 'officialTitle': 'Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)', 'acronym': 'CHIPPI'}, 'statusModule': {'statusVerifiedDate': '2024-06', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-08-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-08-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2019-02-13', 'studyFirstSubmitQcDate': '2019-02-14', 'studyFirstPostDateStruct': {'date': '2019-02-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-06-03', 'lastUpdatePostDateStruct': {'date': '2024-06-04', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Centre Oscar Lambret', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is a phase III, multicenter, interventional and randomized study which evaluates the use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) coupled with either Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS), in patients with ovarian cancer. This study aims to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC combined with standard care (PDS or IDS) or standard care alone.', 'detailedDescription': 'The primary objective of this study is to assess the efficacy, in terms of disease-free survival (DFS), the use of HIPEC treatment combined with standard care (PDS or IDS) or standard care alone (PDS or IDS alone).\\n\\nSecondary objectives of the study include:\\n\\n* Evaluating the efficacy of HIPEC in terms of overall survival (OS) in combination with standard of care\\n* Evaluating the morbidity associated with HIPEC.\\n* Evaluating the trade-off between efficacy and morbidity using the Q-TWiST approach.\\n* Evaluating the impact of HIPEC in terms of quality of life.\\n\\nExploratory objectives (optional) include:\\n\\n* Evaluating the impact of HIPEC on the count of residual viable cells (evaluated by flow cytometry) in abdominal drainage fluids for patients recruited in Centre Oscar Lambret only.\\n* Constituting a biobank (tumoral samples and blood samples) for future translational researches'}, 'conditionsModule': {'conditions': ['Ovary Neoplasms', 'Ovarian Cancer', 'Ovarian Carcinoma'], 'keywords': ['Ovarian cancer', 'Hyperthermic intraperitoneal chemotherapy', 'HIPEC', 'Primary Debulking Surgery', 'Interval Debulking Surgery']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 362, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Arm A (PDS or IDS + HIPEC)', 'type': 'EXPERIMENTAL', 'description': 'Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy (standard care) + HIPEC (hyperthermic intraperitoneal chemotherapy)\\n\\nPatients in this experimental arm will receive surgery (either PDS or IDS) and Neo and/or Adjuvant chemotherapy (CT) (as per standard care) combined with HIPEC. Patients undergoing PDS will also be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).\\n\\nPatient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.', 'interventionNames': ['Drug: HIPEC']}, {'label': 'Arm B (PDS or IDS)', 'type': 'NO_INTERVENTION', 'description': 'Surgery (Primary Debulking Surgery (PDS) or Interval Debulking Surgery (IDS)) + Neo or Adjuvant chemotherapy ONLY (standard care, without HIPEC)\\n\\nPatients in the control group will ONLY receive the standard care, which consists of surgery (PDS or IDS) with Neo and/or Adjuvant chemotherapy (CT). Patients undergoing PDS will be receiving 6 cycles adjuvant CT according to the standard care (ideally 6 weeks post-surgery).\\n\\nPatient undergoing IDS will start with 6 cycles of neo-adjuvant CT with a 3 - 5 weeks washout period (4 - 6 weeks if administered Bevacizumab) prior to surgery. They may also undergo additional adjuvant CT post-surgery according to the standard care.'}], 'interventions': [{'type': 'DRUG', 'name': 'HIPEC', 'description': 'HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40Â°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.\\n\\nAdministration of the dose should be according the following schedule:\\n\\n* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.\\n* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.', 'armGroupLabels': ['Arm A (PDS or IDS + HIPEC)'], 'otherNames': ['Hyperthermic intraperitoneal chemotherapy']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Disease-free Survival (DFS)', 'description': 'The DFS will be measured to assess the efficacy of the combination treatment of surgery and HIPEC or standard care alone.', 'timeFrame': 'From randomization to first progression, relapse or death from any cause, whichever came first, assessed up to 5 years. (Follow-up up to 5 years)'}], 'secondaryOutcomes': [{'measure': 'Overall survival', 'description': 'The overall survival will be measured to assess the efficacy of HIPEC in combination with standard care.', 'timeFrame': 'From randomization to first progression, relapse or death from any cause , whichever came first, assessed up to 5 years..'}, {'measure': 'Adverse events (AE)', 'description': 'The adverse events (AE) are collected to evaluate the impact of HIPEC on the safety and on the feasibility of adjuvant treatment (if any) is planned after surgery.', 'timeFrame': 'Covers the whole treatment duration from Randomization up to the end of treatment (surgery or CT) plus 30 days.'}, {'measure': 'Q-TWiST', 'description': 'Q-Twist (Quality-adjusted time without symptoms of disease or toxicity) will be calculated from the survival tile (OS and DFS) and AE (adverse events) data.', 'timeFrame': 'Over the 5 year surveillance period'}, {'measure': 'Quality of life of the patient (QLQC30)', 'description': 'European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Score 30 (QLQ-C30) will be used to measure the quality of life of the patients.', 'timeFrame': 'Up to 2 years after the end of treatment (every 3 month)'}, {'measure': 'Quality of life of the patient (QLQOV28)', 'description': 'European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Ovarian Cancer Module (QLQ-OV28) will be used to measure the quality of life of the patients.', 'timeFrame': 'Up to 2 years after the end of treatment (every 3 month)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\nPre-eligibility criteria to be checked before surgery for pre-registration\\n\\n1. Age â‰¥18 years and â‰¤ 76 years\\n2. Histologically proven primary epithelial ovarian carcinoma or fallopian tube carcinoma or peritoneal carcinoma (including serous papillary adenocarcinoma, clear-cell carcinoma, mucinous adenocarcinoma and endometrioid carcinoma)\\n3. Pre-therapeutic FIGO (International Federation of Gynecology and Obstetrics) stage III\\n4. Patient eligible for\\n\\n   1. Primary Debulking Surgery (PDS) with planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy\\n   2. Or Interval Debulking Surgery (IDS) after neo-adjuvant chemotherapy +/- bevacizumab or other targeted therapy, with or without planned adjuvant chemotherapy +/- bevacizumab or other targeted therapy. In case of neo-adjuvant chemotherapy, surgery should be performed in a time interval of 3 to 5 weeks in case of chemotherapy without bevacizumab, and in a time interval of 4 to 6 weeks if chemotherapy is combined with bevacizumab. The patient remains eligible for the study if surgery is delayed beyond the recommended time interval.\\n5. WHO (World Health Organization Performance Status) â‰¤ 2\\n6. Physical status score ASA (American Society of Anesthesiologists) â‰¤ 2\\n7. Adequate bone marrow and renal function, as evidenced by the following tests performed within 7 days prior to surgery:\\n\\n   * Absolute Neutrophil Count (ANC) â‰¥1,500/mm3\\n   * Platelets â‰¥100,000/mm3\\n   * Aspartate aminotransferase (ALT)/ Alanine aminotransferase (ALT) â‰¤2.5 Ã— upper limit of normal (ULN) (â‰¤5.0 Ã— ULN in case of liver metastases)\\n   * Total bilirubin â‰¤1.5 Ã— ULN (except in case of Gilbert\\'s disease)\\n   * Creatinine clearance â‰¥ 60 mL/ min\\n8. Negative serum pregnancy test within 7 days prior to surgery for women of childbearing potential. For non-menopausal women, if no hysterectomy is planned, willing to accept the use of an effective contraceptive regimen during the treatment period and at least 6 months after the end of treatment (surgery or adjuvant chemotherapy)\\n9. Absence of contraindication to receive the products used in this study (cisplatin and products used in neo-adjuvant/ adjuvant chemotherapy) according to the most recent SmPC (Summary of Product Characteristics) of these products\\n10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow-up\\n11. Signed written informed consent\\n12. Patient covered by the French or Belgian \"Social Security\" regime Criteria to be checked per-operatively for confirmation of enrolment and randomization\\n13. Residual disease after surgery (cytoreduction score CC) CC-0 (no macroscopic residue) or CC-1 (residue \\\\< 2.5 mm)\\n14. Per-operative hemorrhage \\\\< 2.5 L\\n15. Strictly less than 3 digestive resections performed during surgery\\n16. Diuresis maintained during surgery, without oliguria or anuria (per-operatory diuresis â‰¥ 0,5 mL/ kg/ h)\\n\\nExclusion Criteria:\\n\\n1. Benign disease, borderline disease, non epithelial ovarian carcinoma or carcinosarcoma\\n2. Cirrhosis\\n3. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation\\n4. Auditory impairment\\n5. Dehydration or intercurrent disease that contraindicates hyperhydration (including cardio-respiratory disease)\\n6. Other uncontrolled intercurrent disease including, but not limited to: diabetes; hypertension; symptomatic congestive heart or pulmonary failure; renal, hepatic or severe gastrointestinal (associated with diarrhea) chronic disease\\n7. Any unresolved NCI-CTCAE Grade â‰¥ 2 toxicity from previous anticancer therapy (excluding alopecia)\\n8. Concomitant treatment with prophylactic phenytoin\\n9. Receipt of live attenuated vaccine, including yellow fever vaccine, within 30 days prior to inclusion (and, if patient is enrolled, up to 30 days after the last administration of study treatment)\\n10. Pregnant or breastfeeding woman\\n11. Psychiatric illness or social situation that would limit compliance with study requirement, substantially increase the risk of side effects, or compromise the ability of the patient to give written informed consent\\n12. Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)\\n13. Person under guardianship', 'healthyVolunteers': False, 'sex': 'FEMALE', 'genderBased': True, 'genderDescription': 'Women with ovarian cancer', 'minimumAge': '18 Years', 'maximumAge': '76 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Marie VANSEYMORTIER', 'role': 'CONTACT', 'phone': '+33 3 20 29 59 18', 'email': 'promotion@o-lambret.fr'}, {'name': 'Fabrice MULOT', 'role': 'CONTACT', 'phone': '+33 3 20 29 59 18', 'email': 'promotion@o-lambret.fr'}], 'overallOfficials': [{'name': 'Fabrice NARDUCCI, MD', 'affiliation': 'Centre Oscar Lambret, Lille, France', 'role': 'STUDY_DIRECTOR'}], 'locations': [{'facility': 'Cliniques universitaires St-Luc, Institut Roi Albert II', 'status': 'RECRUITING', 'city': 'Bruxelles', 'zip': '1200', 'country': 'Belgium', 'contacts': [{'name': 'Florence FONTAINE', 'role': 'CONTACT', 'phone': '+32 02 764 85 09', 'email': 'florence.fontaine@uclouvain.be'}, {'name': 'Karoline AMANN', 'role': 'CONTACT', 'email': 'karoline.amann@uclouvain.be'}], 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'facility': \"Institut de CancÃ©rologie de l'Ouest\", 'status': 'RECRUITING', 'city': 'Angers', 'zip': '49055', 'country': 'France', 'contacts': [{'name': 'Romuald WERNERT, MD', 'role': 'CONTACT', 'email': 'romuald.wernert@ico.unicancer.fr'}, {'name': 'Romuald WERNERT, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Pedro RARO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Valeria DE FRANCO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Augustin REYNARD, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Patrick SOULIE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sophie ABADIE-LACOURTOISIE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Paule AUGEREAU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Anne PATSOURIS, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Elouen BOUGHALEM, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'FrÃ©dÃ©ric BIGOT, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Margot NOBLECOURT, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Victor SIMMET, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Marion DE VRIES, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 47.46667, 'lon': -0.55}}, {'facility': 'Institut BergoniÃ©', 'status': 'NOT_YET_RECRUITING', 'city': 'Bordeaux', 'zip': '33076', 'country': 'France', 'contacts': [{'name': 'Coriolan LEBRETON', 'role': 'CONTACT', 'email': 'c.lebreton@bordeaux.unicancer.fr'}, {'role': 'CONTACT', 'email': 'f.guyon@bordeaux.unicancer.fr'}], 'geoPoint': {'lat': 44.84044, 'lon': -0.5805}}, {'facility': 'Centre FranÃ§ois Baclesse', 'status': 'RECRUITING', 'city': 'Caen', 'zip': '14076', 'country': 'France', 'contacts': [{'name': 'Sandrine MARTIN-FRANCOISE, MD', 'role': 'CONTACT', 'email': 'marsa@baclessse.unicancer.fr'}, {'name': 'Sandrine MARTIN-FRANCOISE, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Jean FranÃ§ois LE BRUN, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Florence JOLY, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Emeline MERIAUX, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'facility': 'Centre Jean Perrin', 'status': 'RECRUITING', 'city': 'Clermont-Ferrand', 'zip': '63011', 'country': 'France', 'contacts': [{'name': 'Christophe POMEL, MD', 'role': 'CONTACT', 'email': 'christophe.pomel@clermont.unicancer.fr'}, {'name': 'Christophe POMEL, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Caroline CORNOU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sophie DUBOIS, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Morgane MASSON, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Marie-Ange MOURET-REYNIER, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 45.77966, 'lon': 3.08628}}, {'facility': 'Centre Oscar Lambret', 'status': 'RECRUITING', 'city': 'Lille', 'zip': '59020', 'country': 'France', 'contacts': [{'name': 'Fabrice NARDUCCI, MD', 'role': 'CONTACT', 'email': 'f-narducci@o-lambret.fr'}, {'name': 'Fabrice NARDUCCI, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Delphine HUDRY, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Eric LEBLANC, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Cyril ABDEDDAIM, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Annick CHEVALIER-PLACE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alfred BASSIL, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Charlotte BELLIER, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'ValÃ©rie CHEVALIER-EVAIN, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Emilie KACZMAREK, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Samira MAKHLOUFI, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'HÃ´pital Jeanne de Flandre', 'status': 'RECRUITING', 'city': 'Lille', 'zip': '59037', 'country': 'France', 'contacts': [{'name': 'Pierre COLLINET, MD, PhD', 'role': 'CONTACT', 'email': 'pierre.collinet@chru-lille.fr'}, {'name': 'Pierre COLLINET, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Clarisse EVENO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'JÃ©rÃ´me PHALIPPOU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Christophe DESAUW, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Anne PLOQUIN, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 50.63297, 'lon': 3.05858}}, {'facility': 'Institut Paoli Calmettes', 'status': 'RECRUITING', 'city': 'Marseille', 'zip': '13273', 'country': 'France', 'contacts': [{'name': 'Eric LAMBAUDIE, MD, PhD', 'role': 'CONTACT', 'email': 'lambaudiee@ipc.unicancer.fr'}, {'name': 'Eric LAMBAUDIE, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Gilles HOUVENAEGHEL, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Guillaume BLACHE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Laura SABIANI, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Julien BARROU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Maria Antonietta CAPPIELLO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Magali PROVANSAL, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'FrÃ©dÃ©rique ROUSSEAU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Renaud SABATIER, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 43.29551, 'lon': 5.38958}}, {'facility': \"ICM-Val d'Aurelle\", 'status': 'RECRUITING', 'city': 'Montpellier', 'zip': '34298', 'country': 'France', 'contacts': [{'name': 'Pierre-Emmanuel COLOMBO, MD', 'role': 'CONTACT', 'email': 'Pierre-Emmanuel.Colombo@icm.unicancer.fr'}, {'name': 'Pierre-Emmanuel COLOMBO, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'SÃ©bastien CARRERE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Anne MOURREGOT, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'FranÃ§ois QUENET, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Philippe ROUANET, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Olivia SGARBURA, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': \"VÃ©ronique D'HONDT, MD\", 'role': 'SUB_INVESTIGATOR'}, {'name': 'Michel FABBRO, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 43.61092, 'lon': 3.87723}}, {'facility': 'HÃ´pital EuropÃ©en Georges Pompidou', 'status': 'RECRUITING', 'city': 'Paris', 'zip': '75008', 'country': 'France', 'contacts': [{'name': 'Anne-Sophie BATS, MD', 'role': 'CONTACT', 'email': 'anne-sophie.bats@aphp.fr'}, {'name': 'Anne-Sophie BATS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Nicolas DELANOY, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Henri AZAIS, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Enrica BENTIVEGNA, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Meriem KOUAL, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'HuyÃªn-Thu NGUYEN-XUAN, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Centre Hospitalier Lyon Sud', 'status': 'RECRUITING', 'city': 'Pierre-BÃ©nite', 'zip': '69495', 'country': 'France', 'contacts': [{'name': 'Naoual BAKRIN, MD', 'role': 'CONTACT', 'email': 'naoual.bakrin@chu-lyon.fr'}, {'name': 'Witold GERTYCH, MD', 'role': 'CONTACT', 'email': 'witold.gertych@chu-lyon.fr'}, {'name': 'Naoual BAKRIN, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Witold GERTYCH, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Olivier GLEHEN, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Vahan KEPENEKIAN, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Benoit YOU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Pierre DESCARGUES, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Pierre-Adrien BOLZE, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 45.7009, 'lon': 4.82511}}, {'facility': 'Clinique Mathilde', 'status': 'RECRUITING', 'city': 'Rouen', 'zip': '76100', 'country': 'France', 'contacts': [{'name': 'BenoÃ®t RESCH, MD', 'role': 'CONTACT', 'email': 'benoit.resch@clinique-mathilde.fr'}, {'name': 'BenoÃ¯t RESCH, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Marc BARON, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Julien COGET, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Clotilde HENNETIER, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Morgane PERRIN, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jean Jacques TUECH, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alexandre MARQUE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sandrine MEZZANI, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'CÃ©cile HENNEBERT, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'facility': 'Centre Henri Becquerel', 'status': 'RECRUITING', 'city': 'Rouen', 'country': 'France', 'contacts': [{'name': 'Agathe CROUZET, MD', 'role': 'CONTACT', 'email': 'agathe.crouzet@chb.unicancer.fr'}, {'name': 'Agathe CROUZET, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Julien CARRILHO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Emmanuel DE GOURNAY, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Albane POTEAU, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Laetitia AUGUSTO, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sophie GOUERANT, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'CÃ©cile GUILLEMET, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Marianne LEHEURTEUR, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Camille PETRAU, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 49.44313, 'lon': 1.09932}}, {'facility': \"Institut de CancÃ©rologie de l'Ouest\", 'status': 'WITHDRAWN', 'city': 'Saint-Herblain', 'zip': '44800', 'country': 'France', 'geoPoint': {'lat': 47.21765, 'lon': -1.64841}}, {'facility': 'HÃ´pital de Hautepierre', 'status': 'NOT_YET_RECRUITING', 'city': 'Strasbourg', 'country': 'France', 'contacts': [{'name': 'ChÃ©rif AKLADIOS, MD', 'role': 'CONTACT', 'email': 'Cherif.AKlADlOS@chru-strasbourg.fr'}, {'name': 'Thomas BOISRAME, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'ChÃ©rif AKLADIOS, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Lauriane EBERST, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 48.58392, 'lon': 7.74553}}, {'facility': 'Institut de CancÃ©rologie de Lorraine', 'status': 'RECRUITING', 'city': 'VandÅ“uvre-lÃ¨s-Nancy', 'zip': '54519', 'country': 'France', 'contacts': [{'name': 'FrÃ©dÃ©ric MARCHAL, MD', 'role': 'CONTACT', 'email': 'f.marchal@nancy.unicancer.fr'}, {'name': 'FrÃ©dÃ©ric MARCHAL, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Yolanda FERNANDEZ DIEZ, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'CÃ©line GAVOILLE, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Marie-Christine KAMINSKY, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'CÃ©cilia CERIBELLI, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 48.65, 'lon': 6.18333}}, {'facility': 'Institut Gustave Roussy', 'status': 'WITHDRAWN', 'city': 'Villejuif', 'zip': '94805', 'country': 'France', 'geoPoint': {'lat': 48.7939, 'lon': 2.35992}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010051', 'term': 'Ovarian Neoplasms'}, {'id': 'D000077216', 'term': 'Carcinoma, Ovarian Epithelial'}, {'id': 'D000084462', 'term': 'Hyperthermia'}, {'id': 'D005334', 'term': 'Fever'}], 'ancestors': [{'id': 'D004701', 'term': 'Endocrine Gland Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D010049', 'term': 'Ovarian Diseases'}, {'id': 'D000291', 'term': 'Adnexal Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D000091662', 'term': 'Genital Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D002277', 'term': 'Carcinoma'}, {'id': 'D009375', 'term': 'Neoplasms, Glandular and Epithelial'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D001832', 'term': 'Body Temperature Changes'}, {'id': 'D018882', 'term': 'Heat Stress Disorders'}, {'id': 'D014947', 'term': 'Wounds and Injuries'}], 'browseLeaves': [{'id': 'M5534', 'name': 'Carcinoma', 'relevance': 'LOW'}, {'id': 'M12974', 'name': 'Ovarian Neoplasms', 'asFound': 'Ovarian Cancer', 'relevance': 'HIGH'}, {'id': 'M1704', 'name': 'Carcinoma, Ovarian Epithelial', 'asFound': 'Ovarian Cancer', 'relevance': 'HIGH'}, {'id': 'M8464', 'name': 'Fever', 'asFound': 'Hyperthermic', 'relevance': 'HIGH'}, {'id': 'M2454', 'name': 'Hyperthermia', 'asFound': 'Hyperthermic', 'relevance': 'HIGH'}, {'id': 'M7863', 'name': 'Endocrine Gland Neoplasms', 'relevance': 'LOW'}, {'id': 'M12972', 'name': 'Ovarian Diseases', 'relevance': 'LOW'}, {'id': 'M3643', 'name': 'Adnexal Diseases', 'relevance': 'LOW'}, {'id': 'M8943', 'name': 'Genital Diseases, Female', 'relevance': 'LOW'}, {'id': 'M2876', 'name': 'Genital Diseases', 'relevance': 'LOW'}, {'id': 'M2875', 'name': 'Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M27093', 'name': 'Female Urogenital Diseases', 'relevance': 'LOW'}, {'id': 'M14127', 'name': 'Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8399', 'name': 'Female Urogenital Diseases and Pregnancy Complications', 'relevance': 'LOW'}, {'id': 'M8945', 'name': 'Genital Neoplasms, Female', 'relevance': 'LOW'}, {'id': 'M17315', 'name': 'Urogenital Neoplasms', 'relevance': 'LOW'}, {'id': 'M7862', 'name': 'Endocrine System Diseases', 'relevance': 'LOW'}, {'id': 'M9163', 'name': 'Gonadal Disorders', 'relevance': 'LOW'}, {'id': 'M12320', 'name': 'Neoplasms, Glandular and Epithelial', 'relevance': 'LOW'}, {'id': 'M12315', 'name': 'Neoplasms by Histologic Type', 'relevance': 'LOW'}, {'id': 'M5111', 'name': 'Body Temperature Changes', 'relevance': 'LOW'}, {'id': 'M24916', 'name': 'Stress Disorders, Traumatic', 'relevance': 'LOW'}, {'id': 'M20924', 'name': 'Heat Stress Disorders', 'relevance': 'LOW'}, {'id': 'M17685', 'name': 'Wounds and Injuries', 'relevance': 'LOW'}, {'id': 'T4352', 'name': 'Ovarian Cancer', 'asFound': 'Ovarian Cancer', 'relevance': 'HIGH'}, {'id': 'T4354', 'name': 'Ovarian Epithelial Cancer', 'asFound': 'Ovarian Cancer', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC04', 'name': 'Neoplasms'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BXS', 'name': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'abbrev': 'BC19', 'name': 'Gland and Hormone Related Diseases'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC26', 'name': 'Wounds and Injuries'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'Rare', 'name': 'Rare Diseases'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M6182', 'name': 'Cisplatin', 'relevance': 'LOW'}, {'id': 'M246', 'name': 'Bevacizumab', 'relevance': 'LOW'}, {'id': 'M256801', 'name': 'Sodium thiosulfate', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'ANeo', 'name': 'Antineoplastic Agents'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}, {'abbrev': 'Infe', 'name': 'Anti-Infective Agents'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05525182', 'orgStudyIdInfo': {'id': 'GNC_ESE_COVID19_P2-301'}, 'organization': {'fullName': 'Genencell Co. Ltd.', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy and Safety of ES16001 in Patients With COVID-19', 'officialTitle': 'Efficacy and Safety of ES16001 in Patients With COVID-19: a Phase II/III, Multinational, Randomized, Parallel-group, Double-blind, Placebo-controlled Study'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2021-07-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-07-21', 'studyFirstSubmitQcDate': '2022-08-31', 'studyFirstPostDateStruct': {'date': '2022-09-01', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-21', 'lastUpdatePostDateStruct': {'date': '2023-02-22', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Genencell Co. Ltd.', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This is phase II/III, randomized, parallel-group, double-blind, placebo-controlled study. Patients must be at least 19 years of age (or according to the legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcription polymerase chain reaction (RT-PCR) analysis of rhinopharynx samples. RT-PCR analysis of rhinopharynx samples must be \\\\<4 days old prior to the study enrolment', 'detailedDescription': 'After obtaining the consent and confirming eligibility, eligible patients will be treated with investigational medicinal product (IMP) for 7 days and followed up for additional 21 days (total 29 days). Patients who are discharged from the hospital or ending the quarantine may have to visit the investigational site on a pre-determined date for efficacy and safety follow up observation. Final safety and efficacy data will be collected on the last study day (29th Day).\\n\\nIf patients are fully recovered or discharged from the hospital prior to treatment period, all the evaluations on the 7th day/End of Treatment examination treatment shall be performed on the day of discharging.'}, 'conditionsModule': {'conditions': ['COVID-19']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Phase II -Dose-finding Phase II will be enrolled 424 patients (1:1:1:1 ratio) randomly assigned to one of the four treatment groups as follows.\\n\\n* ES16001 480 mg /day\\n* ES16001 720 mg /day\\n* ES16001 960 mg /day\\n* Placebo\\n\\nPhase III In the phase III, safety and efficacy with the dose selected in the phase II will be compared with placebo. In the phase III, about 706 patients will be randomized in 1:1 ratio to test drug or placebo. Randomization will be stratified depending on the well-known risk factors for progression and disease severity of a patient. Final Endpoints and the sample size may be different depending on the results of the phase II.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'Patients, investigator staff and all site personnel will remain blinded to group allocation from randomization until database lock; randomization data will not be accessible by anyone involved in the study unless knowledge of the study treatment is relevant to the safety of the patient', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 706, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Phase II', 'type': 'EXPERIMENTAL', 'description': 'ES16001: 480 mg/day ES16001: 720 mg/day ES16001: 960 mg/day Placebo', 'interventionNames': ['Drug: ES16001 40 mg', 'Drug: ES16001 80 mg', 'Drug: ES16001 160 mg', 'Drug: Placebo']}, {'label': 'Phase III', 'type': 'EXPERIMENTAL', 'description': 'ES16001 Placebo', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'ES16001 40 mg', 'description': 'Composition: Elaeocarpus extract 40mg tablet', 'armGroupLabels': ['Phase II'], 'otherNames': ['40 mg']}, {'type': 'DRUG', 'name': 'ES16001 80 mg', 'description': 'Elaeocarpus extract 80 mg tablet', 'armGroupLabels': ['Phase II'], 'otherNames': ['80 mg']}, {'type': 'DRUG', 'name': 'ES16001 160 mg', 'description': 'Elaeocarpus extract 160 mg tablet', 'armGroupLabels': ['Phase II'], 'otherNames': ['160 mg']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo Tablet: Tablets for oral use indistinguishable from ES16001 in size, appearance, taste and smell', 'armGroupLabels': ['Phase II', 'Phase III']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Phase II', 'description': 'To determine the safe and effective dose of ES16001 versus placebo for the treatment of mild to moderate COVID-19. Proportion of subjects receiving the oxygen aiding treatment (nasal prong or facial mask) for at last 24 hours with oxygen saturation \\\\< 94% in room air prior to oxygen supply\\n\\n* Proportion of subjects requiring invasive machine ventilation as well as the non-invasive machine ventilation\\n* Proportion of subjects applied with high flow oxygen or machine ventilation with oxygen saturation estimated to be less than 94% in room air\\n* Proportion of dead subjects', 'timeFrame': '2 months, last patient in (LPI) (Dec 22,23 respectively + 1 month Tx -> 2 months for database lock (DBL) and clinical study report (CSR)'}, {'measure': 'Phase III', 'description': 'To demonstrate the superiority of ES16001 versus placebo for the treatment of mild to moderate COVID-19. Proportion of subjects receiving the oxygen aiding treatment (nasal prong or facial mask) for at last 24 hours with oxygen saturation \\\\< 94% in room air prior to oxygen supply\\n\\n* Proportion of subjects requiring invasive machine ventilation as well as the non-invasive machine ventilation\\n* Proportion of subjects applied with high flow oxygen or machine ventilation with oxygen saturation estimated to be less than 94% in room air\\n* Proportion of dead subjects', 'timeFrame': '2 months, last patient in (LPI) (Dec 22,23 respectively + 1 month Tx -> 2 months for database lock (DBL) and clinical study report (CSR)'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n1. Those with full understanding of the clinical study and agreeing with the participation of the clinical study voluntarily in writing, or with a deputy granted with legal authority of the relevant patient if he/she is unable to agree with the clinical study in person\\n2. Adults aged at 19 or above at the time of screening examination (according to the legal age for adult in each country)\\n3. Diagnosis of COVID-19 including a positive real time reverse transcription polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome (SARS)-CoV-2 within 4 days prior to administering the investigational produce (IP)\\n4. mild or moderate patients who have the following conditions at screening and confirm at randomization at randomization A. Mild: Those with COVID-19 symptoms relevant to the inclusion criteria 5 without breathing difficulty or other chest radiation examination B. Moderate: Those with disease in respiratory organs in the clinical evaluation or imaging examination (chest radiation examination, etc.) and also relevant to the following conditions\\n\\n   * Higher than 94% of oxygen saturation (Sp02) with room air at screening\\n   * Lower than 30 times/min respiratory frequency at screening\\n5. Those who happen more than one of the following symptoms within 4 days prior to the treatment of investigational medicinal product (IMP) and also have more than one of symptoms within a day prior to the treatment of IMP:\\n\\n   * Fever\\n   * Cough\\n   * Shortness of breath\\n   * Chills\\n   * Muscle pain\\n   * Headache\\n   * Sore throat\\n   * Loss of smell/taste\\n   * Nasal congestion\\n   * Runny nose\\n   * Fatigue\\n   * Nausea or vomiting\\n   * Diarrhea\\n   * Phlegm\\n6. Those being hospitalized or scheduled in hospital or quarantined facilities or home isolated\\n7. Those comply with the clinical study protocol\\n8. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and through 90 days after the last dose of study medication. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. Effective contraception includes an established hormonal therapy or intrauterine device for females, and the use of a barrier contraceptive (i.e. diaphragm or condoms) with spermicide.\\n\\nExclusion Criteria:\\n\\n1. Those with known or suspected hypersensitivity to ES16001 or any of its excipients\\n2. Those with genetic issues with galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption, etc.\\n3. Patients with ECG evidence of a QTcF \\\\> 450 ms in men and \\\\> 470 ms in women and patients with any other risk factors for Torsades de pointes (TdP) (hypokalemia, hypomagnesemia or hypocalcemia, family history of long QT syndrome, low left ventricular ejection fraction, left ventricular hypertrophy, ischemia and slow heart rate)\\n4. Concomitant use of hydroxychloroquine or other drugs known to prolong QT interval throughout the study 5. Suspected active bacterial, fungal, viral, or other infection (besides COVID-19).\\n\\n6. Immunosuppressor or immunomodulatory drugs within the past 3 months (excluding corticosteroids) and patients with autoimmune disease.\\n\\n7. Patients with one of the following severe COVID-19 signs at randomization (based on NIH classification)\\n\\n* Oxygen saturation (SpO2) \\\\<94% of oxygen saturation without oxygen supply in room air\\n* Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) \\\\<300 mmHg\\n* Respiratory frequency \\\\>30 times/min\\n* Parenchyma infiltration\\\\> 50% 8. Patients requiring oxygen treatment (nasal prong, facial mask, and high flow oxygen) or machine respiration (oxygen by NIV or high flow, intubation and mechanical ventilation, and etc.) at randomization 9. Those requiring extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy (CRRT) treatment due to damage on multiple organs with severe illness (respiratory failure, shock, or multiple organ disorder) 10. Those with issues on kidney or liver as follows in the screening\\n\\n  1. Alanine transaminase (ALT) or aspartate aminotransferase (AST) \\\\> 5 x upper limit of normal (ULN) at screening\\n  2. Total bilirubin that is 1.5 x upper limit of normal (ULN) at screening in the blood\\n  3. Serum creatine \\\\> 2mg/dL (\\\\> 176.8 Î¼mol/L) or estimated creatine clearance \\\\< 30ml/min measured or calculated by Cockroft Gault equation 11. Absolute neutrophil count (ANC) \\\\<1000/Î¼L in the screening 12. platelet count \\\\<50,000/Î¼L in the screening 13. Those who are pregnant or breastfeeding 14. Treatment with an investigational product within 5 times half-life or to 30 days from the screening (whichever is longer) 15. Those taking antiviral drugs, anti-inflammatory medicine, or neutralizing antibody that is known to influence the treatment of COVID-19 (refer to 7.4.2 Prohibited medication) 16. Those with chronic disease that is inappropriate for the participation in clinical study judged by the investigator (Uncontrolled diabetes, chronic kidney disease, chronic liver disease, chronic lung disease, chronic cardiovascular disease, blood cancer, chemotherapeutic cancer patients, patients taking immunosuppressants, idiopathic thrombocytopenia, hyperkalemia patients, etc.)', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '19 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jae-Hyun (Jay) Park', 'role': 'CONTACT', 'phone': '+82 (0)70-7712-9784', 'email': 'chadol9270@genencell.co.kr'}, {'name': 'Seonyu Kim', 'role': 'CONTACT', 'phone': '+82 (0)70-7711-9217', 'email': 'sykim@genencell.co.kr'}], 'overallOfficials': [{'name': 'Jae-Hyun Park', 'affiliation': 'Genencell', 'role': 'STUDY_CHAIR'}], 'locations': [{'facility': 'Soon Chun Hyang University Hospital', 'status': 'RECRUITING', 'city': 'Bucheon', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Seong-on Cho, CRA', 'role': 'CONTACT', 'phone': '+82) 032-621-5795'}, {'name': 'Ansoo Jang', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.49889, 'lon': 126.78306}}, {'facility': \"Eunpyeong, St.Mary's Hospital\", 'status': 'RECRUITING', 'city': 'Seoul', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Seong-on Cho, CRA', 'role': 'CONTACT', 'phone': '+82) 02-2030-3372'}, {'name': 'Sanghaak Lee', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'facility': 'Kyung Hee University Medical Center', 'status': 'RECRUITING', 'city': 'Seoul', 'country': 'Korea, Republic of', 'contacts': [{'name': 'Selki Kim, CRA', 'role': 'CONTACT', 'phone': '+82 ) 02-958-9510'}, {'name': 'Misuk Lee', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05539482', 'orgStudyIdInfo': {'id': 'P0039048'}, 'secondaryIdInfos': [{'id': 'COVID1903006-A', 'type': 'OTHER_GRANT', 'domain': 'HMRF'}], 'organization': {'fullName': 'The Hong Kong Polytechnic University', 'class': 'OTHER'}, 'briefTitle': 'Community-Based Health Education Programs for the Early Detection of, and Vaccination Against, COVID-19 and the Adoption of Self-Protective Measures of Hong Kong Residents', 'officialTitle': 'A Multicenter, Cluster-Randomized, Active-Controlled, Single-Blind Trial of Community-Based Health Education Programs for the Early Detection of, and Vaccination Against, COVID-19 and the Adoption of Self-Protective Measures of Hong Kong Residents'}, 'statusModule': {'statusVerifiedDate': '2022-09', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-04-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-10', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-10', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-09-04', 'studyFirstSubmitQcDate': '2022-09-13', 'studyFirstPostDateStruct': {'date': '2022-09-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2022-09-13', 'lastUpdatePostDateStruct': {'date': '2022-09-14', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'XIE Yao Jie Grace', 'investigatorTitle': 'Assistant Professor', 'investigatorAffiliation': 'The Hong Kong Polytechnic University'}, 'leadSponsor': {'name': 'The Hong Kong Polytechnic University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Food and Health Bureau, Hong Kong', 'class': 'OTHER_GOV'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'This study evaluates the community-based health education program in improving early testing for COVID-19, increasing vaccination acceptability and enhancing emergency preparedness and self-protection measures against COVID-19 in HK. We established a partnership with several local community stakeholders and they will be responsible for recruiting participants and implementing educational programs. Half of the community collaborators will receive the core intervention package, and use it as education material. The other half will be encouraged to self-collect and send health information to the participants.', 'detailedDescription': 'This health education program is based on a Community-based Participants Research (CBPR) approach, which is a partnership approach that equitably involves community members and researchers in all aspects of the research process. Given the different cultural, professional or living background of Hong Kong residents, we think this simple, flexible and sustainable approach will effectively mitigate the COVID-19 risk in HK society,\\n\\nAn academic-community collaboration platform with several nongovernmental organizations (NGOs), companies and schools will be established before this study. They will work together to recruit participants, design and implement a series of educational programs aimed at controlling the spread of COVID-19 in the community.'}, 'conditionsModule': {'conditions': ['COVID-19'], 'keywords': ['CBPR', 'health education', 'vaccination rate', 'early-testing', 'self-protection', 'Hong Kong residents']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'The participants recruited by one collaborator will be considered as one cluster. A research assistant will randomly assign the clusters from the NGOs, Schools, and Companies to either the intervention group or the active control group, respectively. After allocation, there will be four clusters in both the intervention and control groups from the NGOs, schools and companies, respectively. This will result in 3 Ã— 4 = 12 clusters for each group (intervention/control). A active control group will be used instead of a standard control group to help motivate the collaborators to implement the program and to avoid a high participant dropout rate.', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'SINGLE', 'maskingDescription': 'All the participants will be blind to the allocation. Participants in the intervention group will receive intervention based on core package, while participants in the control will receive health information which are collected and provided by collaborators. The collaborator also will be told to avoid discussing allocation with the participants.', 'whoMasked': ['PARTICIPANT']}}, 'enrollmentInfo': {'count': 1200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Community-Based Health Education Group', 'type': 'EXPERIMENTAL', 'description': 'The collaborators will design the Community-based education approach (based on the core intervention package). Collaborators will be required to submit a brief standardized proposal to the academic investigators for review and approval, to ensure that all intervention programs have the same core intervention content and can be implemented appropriately. Collaborators will be able to use any reasonable strategies, such as social media platforms, information technology, posters, leaflets, and videos, to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.', 'interventionNames': ['Behavioral: Community-based Health Education based on core intervention package']}, {'label': 'Health Information Sharing Group', 'type': 'ACTIVE_COMPARATOR', 'description': 'The collaborators will design the community-based education approach and deliver health information to the participants. Researchers will provide some information, while collaborators need to self-collect the rest. Collaborators also need to submit a proposal to ensure the feasibility of intervention programs and the accuracy of health information. Collaborators can use any reasonable strategies to implement the programs . The use of incentives will be encouraged to improve participation. Each programs will last for 3 months. A booster session will be conducted at the mid of the intervention.', 'interventionNames': ['Behavioral: Health Information Sharing Group']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Community-based Health Education based on core intervention package', 'description': 'Community-based Health Education will potentially include the following three components:\\n\\n1. A manual of emergency preparedness and self-protection against COVID-19 infection. The main content will include hand washing, mask wearing and social distancing guidelines.\\n2. Early testing. Participants will be trained on how to recognize the early symptoms of COVID-19 and appropriate practice to take in a response, and they will be provided with testing resources.\\n3. Knowledge of vaccines and their benefits and resources for vaccination.\\n\\nCollaborators should design and implement health programs based on the core intervention package.', 'armGroupLabels': ['Community-Based Health Education Group']}, {'type': 'BEHAVIORAL', 'name': 'Health Information Sharing Group', 'description': 'Collaborators are encouraged to collect and share health information to the participants. Shared information should be previewed by researchers.', 'armGroupLabels': ['Health Information Sharing Group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Vaccination rates', 'description': 'The number of participants who received a new dose of COVID-19 vaccine over the total number of participants.', 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'The knowledge towards COVID-19 vaccine', 'description': 'The knowledge towards COVID-19 vaccine will be measured by 15 items in the self-administered questionnaire. All the items are binary- choice Items (1=Ture, 2= False). The total score ranged from 15 to 30 and a higher score indicates poorer knowledge towards COVID-19 vaccine.', 'timeFrame': '3 months'}, {'measure': 'The hesitancy towards COVID-19 vaccine', 'description': 'The hesitancy towards COVID-19 vaccine will be measured by Chinese version of adult Vaccine Hesitancy Scale (aVAS), which includes 10 items of 5-point Likert scale, ranging from least hesitant (1) to most hesitant (5). In total 3 of aVAS are negatively worded and 7 are positively worded. The total score of aVAS is 50 with a score higher than 25 indicated high vaccine hesitancy.', 'timeFrame': '3 months'}, {'measure': 'Perceived confidence of COVID-19 vaccine', 'description': 'The confidence of COVID-19 vaccine will be measured by 11 items with 5-point Likert scale with \"strongly disagree\", \"disagree\", \"neither agree nor disagree\", \"agree\" and \"strongly agree\". The total score ranges from 11 to 55 with higher score indicating higher confidence of COVID-19 vaccine..', 'timeFrame': '3 months'}, {'measure': 'Perceived barriers of receiving COVID-19 vaccine', 'description': 'The perceived barriers of COVID-19 vaccine will be measured by 4 items with 5-point Likert scale with \"strongly disagree\", \"disagree\", \"neither agree nor disagree\", \"agree\" and \"strongly agree\". The total score ranges from 4 to 20 with higher score indicating higher perceived barriers of COVID-19 vaccine..', 'timeFrame': '3 months'}, {'measure': 'The amount of early testing', 'description': 'The amount of early testing will be measured by self-reported number of early-testing with rapid antigen testing (RAT) in a month.', 'timeFrame': '3 months'}, {'measure': 'The levels of acceptability for early testing', 'description': 'The levels of acceptability for early testing will be measured by 3 items with 5-point Likert scale with \"strongly disagree\", \"disagree\", \"neither agree nor disagree\", \"agree\" and \"strongly agree\". The total score ranges from 3 to 15 with higher score indicating higher acceptability of early testing.', 'timeFrame': '3 months'}, {'measure': 'The frequency of washing hands with soap or hand sanitizer', 'description': 'The amount of early testing will be measured by self-reported number of hand-washing behaviors with soap or hand sanitizer per day in the past week.', 'timeFrame': '3 months'}, {'measure': 'The frequency of washing hands with alcohol-based hand rub', 'description': 'The amount of early testing will be measured by self-reported number of hand-washing behaviors with alcohol-based hand rub per day in the past week.', 'timeFrame': '3 months'}, {'measure': 'The knowledge of proper self-protection', 'description': 'The knowledge of proper self-protection correctly will be measured 13 items in the self-administered questionnaire. All the items are binary- choice Items (1=Ture, 2= False). The total score ranged from 13 to 26 and a higher score indicates poorer knowledge of self-protection.', 'timeFrame': '3 months'}, {'measure': 'Stress status', 'description': 'The Perceived Stress Scale (PSS-4) will be used to measure the stress level.', 'timeFrame': '3 months'}, {'measure': 'Anxiety status', 'description': 'Generalized Anxiety Disorder (GAD-2) will be used to measure the level of anxiety.', 'timeFrame': '3 months'}, {'measure': 'Depression status', 'description': 'The Patient Health Questionnaire-2 (PHQ-2) will be used to measure the depression status.', 'timeFrame': '3 months'}, {'measure': \"Participants' satisfactory level\", 'description': \"The participants' satisfactory level will be measured by asking the degree of satisfaction (1-10) in terms of vaccination, early-testing and self-protection.\", 'timeFrame': '3 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'For participants recruited by NGOs and companies, the Inclusion Criteria will be:\\n\\n* HK resident aged 18 years or above;\\n* Agreement to participate in the study and provide written informed consent.\\n\\nThe Exclusion Criteria will be:\\n\\n* Cognitive impairment that inhibits communication with the investigators;\\n* Inability or unwillingness to provide written informed consent.\\n\\nFor participants recruited by schools, the Inclusion Criteria will be:\\n\\n* HK students aged 12 to 18 years and their parents.\\n\\nThe Exclusion Criteria will be:\\n\\n* Cannot provide written informed consent (or assent for the younger students).', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '12 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Yao Jie Xie, PhD', 'role': 'CONTACT', 'phone': '3400 3798', 'phoneExt': '852', 'email': 'grace.yj.xie@poly.edu.hk'}], 'overallOfficials': [{'name': 'Yao Jie Xie, PhD', 'affiliation': 'The Hong Kong Polytechnic University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'The Hong Kong Polytechnic University', 'status': 'RECRUITING', 'city': 'Hung Hom', 'country': 'Hong Kong', 'contacts': [{'name': 'Yao Jie Xie, PhD', 'role': 'CONTACT', 'phone': '(852) 3400 3798', 'email': 'grace.yj.xie@polyu.edu.hk'}, {'name': 'Yao Jie Xie, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 22.30715, 'lon': 114.18532}}]}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}, 'interventionBrowseModule': {'browseLeaves': [{'id': 'M17360', 'name': 'Vaccines', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT05582382', 'orgStudyIdInfo': {'id': 'CMHS_IntMed_DOH/CVDC/2020/1251'}, 'organization': {'fullName': 'United Arab Emirates University', 'class': 'OTHER'}, 'briefTitle': 'Validation of Prognostic Clinical Risk Scores in Predicting Outcome for Patients With COVID-19 at Initial Triage', 'officialTitle': 'Validation of Prognostic Clinical Risk Scores in Predicting Outcomes for Patients Diagnosed With COVID-19 During Initial Triage Assessment'}, 'statusModule': {'statusVerifiedDate': '2023-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2022-10-14', 'studyFirstSubmitQcDate': '2022-10-14', 'studyFirstPostDateStruct': {'date': '2022-10-17', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-02-02', 'lastUpdatePostDateStruct': {'date': '2023-02-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Dr Adnan Agha', 'investigatorTitle': 'Assistant Professor, Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University', 'investigatorAffiliation': 'United Arab Emirates University'}, 'leadSponsor': {'name': 'Dr Adnan Agha', 'class': 'OTHER'}, 'collaborators': [{'name': 'Abu Dhabi Health Services Company', 'class': 'OTHER_GOV'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing Covid-19 pandemic continues to be a global health threat with a massive burden on health care systems resulting in more than six million deaths in 188 countries. Because of wide clinical spectrum of disease severity, having clinically applicable prognostic tools for early identification of patients at high risk of progression to severe / critical illness is essential to guide clinical decision making and resource allocation efforts. So far, clinical prognostic tools have focused on host factors, but more recent data indicated a significant association between SARS-CoV-2 variants and the development of complications such as long COVID.\\n\\nObjectives\\n\\n1. Validation of the ALA \\\\& ALKA prediction tools for initial evaluation of patients diagnosed with COVID-19 infection.\\n2. Comparison of performance of the ALA \\\\& ALKA prediction tools with the currently clinical risk assessment scoring system used during initial evaluation of patients diagnosed with COVID-19 infection.\\n3. Evaluation of the clinical risk assessment scoring based on number of comorbidities in prediction of COVID-19 related complications\\n4. Assessment of the association between SARS-CoV-2 variants and the risk of COVID-19 severity\\n5. Assessment of the impact of SARS-CoV-2 variants on the performance of ALA \\\\& ALKA prediction tools\\n\\nMethods Data will be abstracted from electronic medical records including demographics, clinical manifestation, comorbidities, and initial laboratory data in patients with Covid 19 infection of around 2000 patients presented initially to COVID assessment centre, including SARS CoV-2 sequencing data. Furthermore, population level SARS-CoV-2 RNA sequence data will also be examined and correlated with COVID-19 severity and the performance of prediction tools.', 'detailedDescription': \"Background:\\n\\nSince December 2019, when severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing COVID -19 disease emerged in Wuhan city and on 11 March 2020 rapidly spread into the rest of the world including UAE as a pandemic. COVID-19 continues to be a global health threat with a massive burden on health care systems resulting in more than six million deaths in 188 countries (1).\\n\\nCOVID-19 infection is characterized by a wide clinical spectrum of disease severity ranging from asymptomatic illness to severe disease that may progress to life-threatening complications such as shock and acute respiratory distress syndrome (2). Thus, having clinically applicable prognostic tools for early identification of symptomatic patients at high risk of progression to severe / critical illness is essential to guide allocating limited healthcare resources (3). So far, clinical prognostic tools have focused on host factors, but more recent data indicated a significant association between SARS-CoV-2 variants and the development of complications such as long COVID (4).\\n\\nCurrently, the clinical assessment for patients with COVID-19 infection is based on patient's age, number of comorbidities, subjective symptoms, and extent of pulmonary infiltrate on radiological examination which makes early prediction of severe / critical illness rather difficult (5-7). A recently published prognostic prediction tools (ALA \\\\& ALKA) were proposed to aid triaging patients with COVID-19 infection on initial diagnosis (8). These prediction tools are based on simple readily available laboratory tests and therefore may offer a clear advantage over other tools to guide discharge and admission decisions in triage assessment centers Nevertheless, external validation of these simple tools using another cohort of patients would provide a stronger evidence to support their utility in triaging patients on initial diagnosis. In addition, it will also allow further optimization of these tools to improve their utility as clinical decision support tools to triage patients on initial diagnosis. Patients deemed to be high risk based on these predictive tools could be triaged to hospital admission where intensive care unit (ICU) is available in anticipation of worse outcome. Therefore, these patients may benefit from earlier initiation of the required level of care and support including specific therapy.\\n\\nThe aim of this study is to validate and compare the ALA \\\\& ALKA prediction tools with the currently clinical risk assessment scoring system proposed for initial evaluation of patients with COVID-19 infection.\\n\\nMethodology:\\n\\nAn observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . Furthermore, population level SARS-CoV-2 RNA sequence data will also be examined and correlated with COVID-19 severity and the performance of prediction tools.\\n\\nData will be abstracted from electronic medical records using a data collection tool. This includes demographics, clinical manifestation, number of comorbidities, initial laboratory and radiological examination results and their final outcomes as detailed below.\\n\\nThe risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \\\\& ALKA and compared with the currently proposed clinical risk assessment scoring system\\n\\nThe utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:\\n\\n1. Hospital admission on the first encounter to ED\\n2. Admission to ICU for the duration of the COVID-19 hospitalization\\n3. In hospital and out of hospital mortality\\n4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)\\n\\nSample Collection Process:\\n\\nData will be abstracted from electronic medical records using a data collection tool. The data would include demographics, clinical manifestation, comorbidities, laboratory and radiological results, and final outcomes.\\n\\nThe assessment risk score at initial presentation will be calculated using a free web-based online calculator.\\n\\nData Handling \\\\& Analysis:\\n\\nDescriptive statistics will be generated for all variables. Multivariate logistic regression models to fit for outcomes. Variables incorporated in the COVID-19 risk of score will be included in the regression analysis to predict the outcomes. Multivariate logistic regression results will be presented in terms of adjusted Odds Ratios with corresponding 95% confidence intervals and p-values.\\n\\nDiscrimination will be evaluated using C-Statistic, along with its corresponding 95% Confidence Intervals and Receiver Operating Characteristic (ROC) curve. C-Statistics â‰¥ 0.7 will be considered good and â‰¥ 0.8 will be considered excellent (9). Calibration will be assessed based on the predicted probability for the outcome as predicted from the regressions. Calibration curves will be generated. P-values \\\\<0.05 is considered statistically significant. All analysis will be performed using SPSS software (version 28, IBM Corp, NY, USA).\"}, 'conditionsModule': {'conditions': ['COVID-19'], 'keywords': ['hospitalization', 'COVID-19', 'clinical risk score', 'morbidity', 'prediction']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 2000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'interventions': [{'type': 'OTHER', 'name': 'logistic regression of known prognostic markers of severity of COVID19', 'description': 'An observational longitudinal follow up of all consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department . The risk assessment score at initial presentation will be calculated for each patient using clinical assessment scoring of ALA \\\\& ALKA and compared with the currently proposed clinical risk assessment scoring system\\n\\nThe utility of the risk score in triaging patients on their initial visits to emergency department (ED) will be validated against the following measured outcomes:\\n\\n1. Hospital admission on the first encounter to ED\\n2. Admission to ICU for the duration of the COVID-19 hospitalization\\n3. In hospital and out of hospital mortality\\n4. Return to ED following initial discharge (within the current covid illness period, Maximum 30 days from the initial diagnosis)'}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Validation of the ALA & ALKA prediction tools', 'description': 'Validation of the ALA \\\\& ALKA prediction tools for initial evaluation of patients diagnosed with COVID-19 infection', 'timeFrame': '12 months'}], 'secondaryOutcomes': [{'measure': 'Comparison of performance of the ALA & ALKA prediction tools with current clinical risk tools', 'description': 'Comparison of performance of the ALA \\\\& ALKA prediction tools with the currently clinical risk assessment scoring system used during initial evaluation of patients diagnosed with COVID-19 infection.', 'timeFrame': '12 months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* All consecutive patients with positive SARS-CoV-2 testing on nasopharyngeal swabs per WHO definitions presenting to the emergency department\\n* All patients admitted to the hospital for isolation purposes only\\n\\nExclusion Criteria:\\n\\n* Inconclusive PCR results on initial or repeat results with 24 hours', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '16 Years', 'maximumAge': '99 Years', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'studyPopulation': 'The sample will include all consecutive symptomatic patients with confirmed COVID-19 infection presented to ED. A sample size of 2000 is required for the validation of the prognostic predictive tools.\\n\\nSample Collection Process:\\n\\nData will be abstracted from electronic medical records using a data collection tool. The data would include demographics, clinical manifestation, comorbidities, laboratory and radiological results, and final outcomes.\\n\\nThe assessment risk score at initial presentation will be calculated using a free web-based online calculator.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Omran Bakoush', 'role': 'CONTACT', 'phone': '+971-3-7673333', 'phoneExt': '7451', 'email': 'Omran.Bakoush@uaeu.ac.ae'}, {'name': 'Adnan Agha', 'role': 'CONTACT', 'phone': '+971-3-7673333', 'phoneExt': '7677', 'email': 'adnanagha@uaeu.ac.ae'}], 'overallOfficials': [{'name': 'Adnan Agha', 'affiliation': 'United Arab Emirates University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Internal Medicine, College of Medicine and Health Sciences', 'status': 'RECRUITING', 'city': 'Al Ain', 'state': 'Abu Dhabi', 'zip': '15551', 'country': 'United Arab Emirates', 'contacts': [{'name': 'Adnan Agha', 'role': 'CONTACT', 'phone': '+971-3-7673333', 'phoneExt': '7677', 'email': 'adnanagha@uaeu.ac.ae'}], 'geoPoint': {'lat': 24.19167, 'lon': 55.76056}}]}, 'referencesModule': {'references': [{'pmid': '32648899', 'type': 'BACKGROUND', 'citation': 'Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.'}, {'pmid': '32997542', 'type': 'BACKGROUND', 'citation': 'Halalau A, Imam Z, Karabon P, Mankuzhy N, Shaheen A, Tu J, Carpenter C. External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. Ann Med. 2021 Dec;53(1):78-86. doi: 10.1080/07853890.2020.1828616. Epub 2020 Oct 9.'}, {'pmid': '35568825', 'type': 'BACKGROUND', 'citation': 'Dardenne N, Locquet M, Diep AN, Gilbert A, Delrez S, Beaudart C, Brabant C, Ghuysen A, Donneau AF, Bruyere O. Clinical prediction models for diagnosis of COVID-19 among adult patients: a validation and agreement study. BMC Infect Dis. 2022 May 14;22(1):464. doi: 10.1186/s12879-022-07420-4.'}, {'pmid': '35223916', 'type': 'BACKGROUND', 'citation': 'Kurban LAS, AlDhaheri S, Elkkari A, Khashkhusha R, AlEissaee S, AlZaabi A, Ismail M, Bakoush O. Predicting Severe Disease and Critical Illness on Initial Diagnosis of COVID-19: Simple Triage Tools. Front Med (Lausanne). 2022 Feb 10;9:817549. doi: 10.3389/fmed.2022.817549. eCollection 2022.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': 'Non identifiable data for this validation study upon completion will be released for researchers including performance of individual markers of severity as well as final model'}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}, {'protocolSection': {'identificationModule': {'nctId': 'NCT04910282', 'orgStudyIdInfo': {'id': '115875'}, 'organization': {'fullName': 'Lawson Health Research Institute', 'class': 'OTHER'}, 'briefTitle': 'Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness', 'officialTitle': 'Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-01-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-12-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2024-12-31', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-05-31', 'studyFirstSubmitQcDate': '2021-05-31', 'studyFirstPostDateStruct': {'date': '2021-06-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-01', 'lastUpdatePostDateStruct': {'date': '2024-02-05', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Lawson Health Research Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The ophthalmology clientele is vulnerable in the context of the coronavirus disease 2019 (COVID-19) pandemic because of their age and comorbidities. Specifically, elderly patients aged 65 and above with glaucoma, age-related macular degeneration, or diabetic retinopathy require regular follow-ups and commonly suffer from additional comorbidities. Further, because of the proximity between the patient and health care personnel during ophthalmological examinations, the risk of infection during visits is significant. The delicate balance between the risk of exposure to COVID-19 and visual loss in delaying cases is a psychological stressor to both patients and clinicians.\\n\\nA cross-sectional study accumulating the data of 425 patients aged 65 and above with various eye diseases will be conducted. Participants will be presented with a set of online questionnaires designed to collect data on health-related quality of life (HRQOL), vision-related quality of life (VRQOL), depression symptoms, anxiety, sleep quality, community integration, and their experience with tele-consultations. This study can help quantify the collateral impact of the COVID-19 beyond the direct impact of the virus, to improve future quality of care guidelines on non-COVID-19 conditions, and to help plan patient prioritization once restrictions are eased.', 'detailedDescription': \"BACKGROUND AND RATIONALE\\n\\nCOVID-19 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Like many healthcare departments, the department ophthalmology presents risk of COVID-19 infection. As a result, the present pandemic has led officials to rethink the management of patient lists and to restrict the patients to be assessed or to be operated based on the urgency of their condition in accordance with ministerial guidelines. A delay in visits might increase the risk of visual loss not only through the delay of necessary care, but also through an increase in non-adherence to treatment. Indeed, patients themselves might decide to interrupt their treatment or postpone their visit for fear of contracting the disease. There is concern not only about compliance to treatment, but also about accessibility issues to medications in high-demand and modifications of treatment protocols.\\n\\nElderly people aged 65 and above are commonly afflicted by many eye diseases with vision loss. Furthermore, during times of the COVID-19 pandemic, this population can be vulnerable to possible vision loss due to a delay of care.\\n\\nAs a result, it is being proposed to perform a cross-sectional study using a sample of patients from this population to gather information on follow-up and treatment delays associated with the pandemic's offloading measures as well as any adverse effects on visual acuity that have occurred during the pandemic. The evidence collected from this study could be translated into clinical practices helping to provide recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.\\n\\nVisual loss, potentially due to the reasons that were mentioned above, can bring about depressive symptoms and deteriorate the quality of life (QOL). In the proposed study, the investigators have included questionnaires to assess the various stressors brought on during the COVID-19 pandemic such as fear of vision loss, health-related QOL, vision-related QOL, depression and anxiety symptoms, sleep quality, number of ER visits for deterioration of mental health. This evidence base collected from this study could, once again, be translated into clinical practices helping to provide recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.\\n\\nSTUDY AIM\\n\\nThrough a cross-sectional survey, the investigators aim to build an evidence base to provide decision-makers with high quality, timely, and relevant evidence and to translate this knowledge into clinical practices by providing real-time knowledge and recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.\\n\\nSTUDY OBJECTIVES AND HYPOTHESES\\n\\nPrimary objectives: To build an evidence base to provide decision-makers with high quality, timely, and relevant evidence and to translate this knowledge into clinical practices by providing real-time knowledge and recommendations to adjust the response to the COVID-19 pandemic in ophthalmological management.\\n\\nSecondary objectives: Using a cross-sectional survey, the investigators will: 1) document the follow-up and treatment delays associated with the pandemic's offloading measures 2) determine whether any adverse effects on visual acuity occurred during the pandemic 3) determine the impact on mental health (e.g. fear of vision loss, health-related QOL, vision-related QOL, depression and anxiety symptoms, sleep quality, number of ER visits for deterioration of mental health) 4) determine the role and impact of virtual care (telemedicine, teleconsultation) in the state of the current pandemic and provide additional data for the long-term implementation of telemedicine in vision care.\\n\\nMETHODOLOGY\\n\\nStudy Design\\n\\nA cross-sectional survey will be performed to gather the data required to build an evidence base to provide decision-makers with high-quality, timely, and relevant evidence, as well as to translate this knowledge into clinical practices.\\n\\nStudy Population and Setting\\n\\nPatients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, similar to the previous and ongoing research studies by the investigators, based on inclusion and exclusion criteria.\\n\\nRecruitment\\n\\nIt is being hoped to complete recruitment within a year of receiving ethics approval. Based on previous experience, it is planned to recruit at an average rate of 4 participants/week in a staggered manner over a 9 to 10-month period.\\n\\nData Fidelity, and Management\\n\\nDay-to-day Management of the Study\\n\\nThe RAs will oversee the coordination and monitoring of the overall study. They will prepare all documents required for informed consent and questionnaire administration. They will also be responsible for recruitment, data management (Qualtrics), data analysis, and preparation of presentations and manuscripts. They will be trained on the TTO, VFQ-25, CES-D, HADS-A, PSQI, and CIQ by the Primary Investigator (PI). They will receive ongoing supervision throughout the study by the PI and the co-investigator with the aim of approaching a reliability level of Intra Class Correlation (ICC) \\\\> .80 on all scales. Weekly meetings will be organized by the investigators to ensure recruitment and progression of the study.\\n\\nFidelity of Assessments\\n\\nThe RAs will be trained and supervised weekly by the PI.\\n\\nRecruitment, Screening, and Consent Process\\n\\n425 eye disease patients will be recruited for this study as described previously in the recruitment procedures section. Physicians at Ivey Eye Institute will identify potential participants based on the inclusion and exclusion criteria, as described previously. The potential participants will be asked whether they wish to participate in the following study. Physicians will then refer the patients expressing interest who meet recruitment criteria to the research assistant (RA) for an in-person interview to obtain informed consent or obtain contact information to obtain informed consent electronically.\\n\\nPotential participants will be presented with an electronic letter of information and consent (LOI). The RA will briefly describe the study to these potential participants and offer to send an electronic copy of the LOI by e-mail. The LOI will contain the contact information of the study investigators and RAs on the front cover page and the study description. In addition, those patients expressing interest will be asked if they consent to providing their contact information (name, phone number, and/or e-mail address). Upon receiving consent to participate in the study, the RA will collect the participant's email and telephone number and present the online survey to be completed.\\n\\nIf the participant presents significant distress (severe depression as confirmed by a CES-D â‰¥ 24), the PI will be required to respond within 48 hours upon receiving the questionnaire result. The participant in distress will be referred to a mental health provider for further screening for presence of imminent suicidality and safety. The mental health provider will determine whether they have suicidal intent (the wish to harm or kill themselves). In the rare event that there is what is considered an imminent risk, such participants will be referred to the Centralized Emergency Psychiatry Service (CEPS) at the Victoria Hospital.\\n\\nOUTCOMES\\n\\nMain Outcomes\\n\\nPrimary Outcomes\\n\\nBuilding an evidence base to provide decision-makers with high quality, timely, and relevant evidence, and translating this knowledge into clinical practices.\\n\\nStudy success criteria: If investigators are able to a) screen at least ten patients per week, (b) at least 60% of eligible patients will be recruited, (c) there will be no more than 30% attrition rate, and additionally if (d) 95% of recruited subjects complete 100% study questionnaires; then study would have been successful.\\n\\nSecondary Outcomes\\n\\nHealth-Related Quality of Life\\n\\nImprovement in Health-Related Quality of Life (HRQOL) score as measured by the Time Trade-Off questionnaire (TTO).\\n\\nVision-Related Quality of Life\\n\\nVision-Related Quality of Life (VRQOL) score as measured by the Visual Function Questionnaire (VFQ-25).\\n\\nDepression\\n\\nDepressive symptoms as measured by in Center for Epidemiologic Studies - Depression (CES-D) scores (\\\\< 16).\\n\\nAnxiety\\n\\nAnxiety symptoms as measured by the Hospital Anxiety and Depression Scale - Anxiety subscale (HADS-A) scores\\n\\nSleep Quality\\n\\nSleep quality as measured by reduction in Pittsburgh Sleep Quality Index (PSQI) scores (â‰¤ 5).\\n\\nCommunity Integration\\n\\nEnhanced community integration as measured by an increase in Community Integration Questionnaire (CIQ) scores.\\n\\nQualitative Measures Outcomes\\n\\nMental health, physical health, patient experience with virtual care, fear of vision loss, and change in vision during the pandemic as measured using 5-point Likert scale multiple-choice format questionnaires.\\n\\nSTATISTICAL ANALYSIS AND SAMPLE SIZE\\n\\nData analysis\\n\\nThe investigators will examine the descriptive statistics for the participants group and check for outliers. It is planned to use a linear-mixed model with the score as the dependent variable, demographic variables as covariates. Univariate and bivariate analysis will be performed for each independent variable against the dependent variable to elicit the impact of each co-variate on the pattern of preference based HRQoL, depression, anxiety, community integration, and sleep quality without adjusting for the effect of other variables. Models will be deemed statistically significant if they are associated with a significant F value (p \\\\< 0.01) and if they explain over 15% variability of the dependent variable. Only those independent variables that are statistically significantly associated with the preference based HRQoL (p \\\\< 0.05) will be used for model construction.\\n\\nSTATA 15.0 will be used to run all statistical analysis. Based on population size of adults with eye diseases above the age of 65 in South Western Ontario, 5% margin of error, and 95% confidence interval, the sample size has been computed to be 384 participants. Given a 10% attrition rate, the study sample size of 425 participants will be adequate. As such, the sample size has been set to n = 425.\\n\\nPOTENTIAL RISKS/ADVERSE EFFECTS\\n\\nRisks and Safety of Participants\\n\\nThere are also no direct risks associated with administering the questionnaires to the participants in this study. It does not involve any procedures or medical tests. It is not anticipated that there will be any increased risk in completing any of the questionnaires. It could be that certain questionnaire items make one remember life events which could be potentially disconcerting. Any indications of serious mental health issues will be reported immediately for further clinical assessment and management. Standard of care will be unaffected and only capable and consenting participants will be recruited into the study. COVID-19 restrictions will be respected including the proper donning of personal protective equipment, and sanitation of surfaces and hands. Potential risks to data collection include a privacy breach since there will be various questionnaires to collect information from patients.\\n\\nPrivacy, Confidentiality, and Data Protection\\n\\nElectronic research records will be stored using QUALTRICS up to a period of 15 years. Study team members may access data on QUALTRICS, download this data and store the data. Any such activities will be done under the direction and supervision of the PI. Data will be coded to protect participant confidentiality.\"}, 'conditionsModule': {'conditions': ['Covid19', 'Eye Diseases'], 'keywords': ['Eye disease patients', 'Psychological stressors', 'COVID-19', 'Seniors']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 425, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Eye Disease Patients', 'description': \"Patients with eye diseases age 65 and above will be included. Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person, based on inclusion and exclusion criteria.\"}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'health-related quality of life (HRQoL)', 'description': 'HRQoL is an essential measure of quality of life related to health; it helps physician identify hidden morbidity in clinical care as well as improves patient-physician communications. HRQoL will be measured using time trade-off questionnaire. It is measured in a scale of 0 to 1, with higher scores indicating a better outcome. This means that 0 indicates poor HRQoL and 1 indicates perfect health.', 'timeFrame': \"Immediately upon receiving the participant's consent to participate in the study\"}], 'secondaryOutcomes': [{'measure': 'Visual Function Score', 'description': 'Visual Function score will be measured using Visual Function Questionnaire (VFQ-25). It is measured in a scale of 0 to 100, with 100 indicating the best possible outcome. This means that 0 indicates poor vision-related QOL and 1 indicates perfect health.', 'timeFrame': \"Immediately upon receiving the participant's consent to participate in the study\"}, {'measure': 'Depression', 'description': 'Depression is a feeling of severe despondency and dejection. Depression will be measured using the Center for Epidemiological Studies - Depression (CES-D) score. It is measured in a scale of 0 to 60, with higher scores indicating a worse outcome. This means that 0 indicates perfect health and 60 indicates severe depression.', 'timeFrame': \"Immediately upon receiving the participant's consent to participate in the study\"}, {'measure': 'Anxiety', 'description': 'Anxiety will be measured using Hospital Anxiety and Depression Scale - Anxiety (HADS-A) subscale. It is scored on a scale of 0 to 21, with higher scores indicating a worse outcome. This means that 0 indicates perfect health and 21 indicates severe anxiety.', 'timeFrame': \"Immediately upon receiving the participant's consent to participate in the study\"}, {'measure': 'Sleep Quality', 'description': 'Sleep quality as measured using the Pittsburgh Sleep Quality Index (PSQI) scores. It is scored in a scale of 0 to 21, with higher scores indicating a worse outcome. This means that 0 indicates perfect health and 21 indicates poor sleep quality.', 'timeFrame': \"Immediately upon receiving the participant's consent to participate in the study\"}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\\n\\n* Patients diagnosed with an eye disease by an experienced ophthalmologist.\\n* Patients with eye diseases age 65 and above.\\n* Be able to provide valid informed consent to participate in the research study.\\n* Being able to read and understand English.\\n* Having no significant self-reported or a physician diagnosed mental health disorder.\\n\\nExclusion Criteria:\\n\\n* Inability to provide a valid informed consent.\\n* Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.\\n* Severe depression as confirmed by a CES-D â‰¥ 24.\\n* Having a lifetime diagnosis of self-reported other serious mental disorders, including bipolar I or II disorder, primary psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder).\\n* Self-reported substance abuse or dependence within the past 3 months.\\n* Having an acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.\\n* Having irreversible vision loss that prevents one from completing the questionnaires.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '65 Years', 'stdAges': ['OLDER_ADULT'], 'studyPopulation': \"Patients from the Ivey Eye Institute, St. Joseph's Health Care London, ON will be recruited in-person based on inclusion and exclusion criteria.\", 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Monali M Malvankar, PhD', 'role': 'CONTACT', 'phone': '5196858500', 'phoneExt': '61288', 'email': 'monali.malvankar@sjhc.london.on.ca'}], 'overallOfficials': [{'name': 'Monali Malvankar', 'affiliation': 'Western University, Canada', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': \"St. Joseph's Hospital\", 'status': 'RECRUITING', 'city': 'London', 'state': 'Ontario', 'zip': 'N6A4V2', 'country': 'Canada', 'contacts': [{'name': 'Monali Malvankar', 'role': 'CONTACT', 'phone': '5196858500', 'phoneExt': '61288'}], 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}]}, 'referencesModule': {'references': [{'pmid': '15955983', 'type': 'BACKGROUND', 'citation': 'Globe DR, Varma R, Torres M, Wu J, Klein R, Azen SP; Los Angeles Latino Eye Study Group. Self-reported comorbidities and visual function in a population-based study: the Los Angeles Latino Eye Study. Arch Ophthalmol. 2005 Jun;123(6):815-21. doi: 10.1001/archopht.123.6.815.'}, {'pmid': '29896314', 'type': 'BACKGROUND', 'citation': 'Sabel BA, Wang J, Cardenas-Morales L, Faiq M, Heim C. Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine. EPMA J. 2018 May 9;9(2):133-160. doi: 10.1007/s13167-018-0136-8. eCollection 2018 Jun.'}, {'pmid': '32631403', 'type': 'BACKGROUND', 'citation': 'Salari N, Hosseinian-Far A, Jalali R, Vaisi-Raygani A, Rasoulpoor S, Mohammadi M, Rasoulpoor S, Khaledi-Paveh B. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Global Health. 2020 Jul 6;16(1):57. doi: 10.1186/s12992-020-00589-w.'}, {'pmid': '32349113', 'type': 'BACKGROUND', 'citation': 'Lam DSC, Wong RLM, Lai KHW, Ko CN, Leung HY, Lee VYW, Lau JYN, Huang SS. COVID-19: Special Precautions in Ophthalmic Practice and FAQs on Personal Protection and Mask Selection. Asia Pac J Ophthalmol (Phila). 2020 Mar-Apr;9(2):67-77. doi: 10.1097/APO.0000000000000280.'}, {'pmid': '32007143', 'type': 'BACKGROUND', 'citation': 'Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.'}, {'type': 'BACKGROUND', 'citation': 'Aylward, Bruce (WHO); Liang, W. (PRC). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020; vol. 2019 16-24.'}, {'pmid': '10414631', 'type': 'BACKGROUND', 'citation': 'Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician. 1999 Jul;60(1):99-108.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': \"The code key with identifying data (ID #, phone #, date of birth, date of first assessment/consent, date of exit from the study, and any adverse events) will be stored in a password-protected and encrypted spreadsheet on the hospital network shared drive.\\n\\nWe do not anticipate the questionnaire data collection to take longer than 12 months, and do not anticipate data analysis to take longer than 12 months thereafter (total of 12 months' time), with an absolute maximum of 15 years in post study completion prior to destruction of the data.\"}}, 'derivedSection': {'miscInfoModule': {'versionHolder': '2024-12-04'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000086382', 'term': 'COVID-19'}, {'id': 'D005128', 'term': 'Eye Diseases'}], 'ancestors': [{'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}], 'browseLeaves': [{'id': 'M2561', 'name': 'COVID-19', 'asFound': 'COVID-19', 'relevance': 'HIGH'}, {'id': 'M8271', 'name': 'Eye Diseases', 'asFound': 'Eye Disease', 'relevance': 'HIGH'}, {'id': 'M16105', 'name': 'Stress, Psychological', 'relevance': 'LOW'}, {'id': 'M13904', 'name': 'Pneumonia', 'relevance': 'LOW'}, {'id': 'M13914', 'name': 'Pneumonia, Viral', 'relevance': 'LOW'}, {'id': 'M10283', 'name': 'Infections', 'relevance': 'LOW'}, {'id': 'M6368', 'name': 'Communicable Diseases', 'relevance': 'LOW'}, {'id': 'M14978', 'name': 'Respiratory Tract Infections', 'relevance': 'LOW'}, {'id': 'M17522', 'name': 'Virus Diseases', 'relevance': 'LOW'}, {'id': 'M20490', 'name': 'Coronavirus Infections', 'relevance': 'LOW'}, {'id': 'M6555', 'name': 'Coronaviridae Infections', 'relevance': 'LOW'}, {'id': 'M23685', 'name': 'Nidovirales Infections', 'relevance': 'LOW'}, {'id': 'M15149', 'name': 'RNA Virus Infections', 'relevance': 'LOW'}, {'id': 'M11168', 'name': 'Lung Diseases', 'relevance': 'LOW'}, {'id': 'M14977', 'name': 'Respiratory Tract Diseases', 'relevance': 'LOW'}, {'id': 'T6034', 'name': 'Quality of Life', 'asFound': 'Quality of Life', 'relevance': 'HIGH'}], 'browseBranches': [{'abbrev': 'BC01', 'name': 'Infections'}, {'abbrev': 'BC08', 'name': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC11', 'name': 'Eye Diseases'}, {'abbrev': 'BXM', 'name': 'Behaviors and Mental Disorders'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}]}}, 'hasResults': False}], 'nextPageToken': 'NF0g5JCGmvMo'}\n",
      "https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+viral+pharyngitis++OR+Viral+sinusitis++OR+Acute+bacterial+sinusitis++OR+Sputum+finding++OR+Fever++OR+Loss+of+taste++OR+Suspected+COVID-19+OR+COVID-19&filter.overallStatus=RECRUITING\n"
     ]
    }
   ],
   "source": [
    "url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "\n",
    "headers = {\n",
    "    \"Content-Type\": \"application/json\", \n",
    "}\n",
    "\n",
    "params = {\n",
    "    \"query.cond\": conditions_str, \n",
    "    \"filter.overallStatus\": [\"RECRUITING\"], \n",
    "}\n",
    "\n",
    "#write function to get the nctID, Official Title, Eligibility Criteria, Disease Characteristics\n",
    "#def extract_clinical_trial_information(dataframe): \n",
    "\n",
    "\n",
    "    \n",
    "    #return None\n",
    "\n",
    "# Make the GET request\n",
    "response = requests.get(url, headers=headers, params=params)\n",
    "\n",
    "# Print response\n",
    "if response.status_code == 200:\n",
    "    print(\"Success:\", response.json())\n",
    "    print(response.request.url) \n",
    "    response_json = response.json()\n",
    "    clinical_df = json_normalize(response_json.get('studies', []))\n",
    "else:\n",
    "    print(f\"Error {response.status_code}: {response.text}\")\n",
    "\n",
    "\n",
    "#final_clinical_df = extract_clinical_trial_information(clinical_trial)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>protocolSection.identificationModule.nctId</th>\n",
       "      <th>protocolSection.identificationModule.briefTitle</th>\n",
       "      <th>protocolSection.identificationModule.officialTitle</th>\n",
       "      <th>protocolSection.descriptionModule.briefSummary</th>\n",
       "      <th>protocolSection.descriptionModule.detailedDescription</th>\n",
       "      <th>protocolSection.conditionsModule.conditions</th>\n",
       "      <th>protocolSection.conditionsModule.keywords</th>\n",
       "      <th>protocolSection.eligibilityModule.eligibilityCriteria</th>\n",
       "      <th>protocolSection.eligibilityModule.sex</th>\n",
       "      <th>protocolSection.eligibilityModule.minimumAge</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT06684431</td>\n",
       "      <td>Study to Evaluate Safety and Immunogenicity of...</td>\n",
       "      <td>A Phase I Study to Evaluate Safety and Immunog...</td>\n",
       "      <td>This First-in-human dose-escalation vaccine ph...</td>\n",
       "      <td>This First-in-human dose-escalation vaccine ph...</td>\n",
       "      <td>[Crimean Congo Hemorrhagic Fever]</td>\n",
       "      <td>[N-pVAX1, Phase I, Dose-escalation]</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Men and women betwee...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05735782</td>\n",
       "      <td>Clinical and Biological Characterization of Po...</td>\n",
       "      <td>Association of Symptoms, Clinical and Biochemi...</td>\n",
       "      <td>The goal of this observational study is to des...</td>\n",
       "      <td>Two groups of cases and one group of controls ...</td>\n",
       "      <td>[Long COVID]</td>\n",
       "      <td>[Post-Acute COVID-19 Syndrome, Long COVID, Pos...</td>\n",
       "      <td>Two groups of cases and one group of controls ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT05505682</td>\n",
       "      <td>Impact of Project Wolbachia - Singapore on Den...</td>\n",
       "      <td>Assessing the Efficacy of Male Wolbachia-infec...</td>\n",
       "      <td>The study is a cluster-randomised controlled t...</td>\n",
       "      <td>The study is designed as a parallel, two-arm, ...</td>\n",
       "      <td>[Dengue]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion criteria:\\n\\n* Dengue-suspected pati...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05787431</td>\n",
       "      <td>Levels of Physical Activity After SARS-CoV-2 I...</td>\n",
       "      <td>Levels of Physical Activity After SARS-CoV-2 I...</td>\n",
       "      <td>Coronavirus infection has an impact on several...</td>\n",
       "      <td>Coronavirus identified in 2019, SARS-CoV-2 (CO...</td>\n",
       "      <td>[COVID-19 (Coronavirus Disease 2019)]</td>\n",
       "      <td>[Physical Activity, exercise, public health, P...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nCOVID-19 recovered indi...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05808231</td>\n",
       "      <td>Effectiveness and Safety of Quinine Sulfate as...</td>\n",
       "      <td>An aDaptive, multicEnter, rAndomized, Open-Lab...</td>\n",
       "      <td>This is a multicenter, randomized, open-label,...</td>\n",
       "      <td>This is an adaptive, multicenter, randomized, ...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[COVID-19, Quinine Sulfate]</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Male and female patie...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>18 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT03842982</td>\n",
       "      <td>Hyperthermic Intraperitoneal Chemotherapy (HIP...</td>\n",
       "      <td>Phase III Randomized Clinical Trial Evaluating...</td>\n",
       "      <td>This is a phase III, multicenter, intervention...</td>\n",
       "      <td>The primary objective of this study is to asse...</td>\n",
       "      <td>[Ovary Neoplasms, Ovarian Cancer, Ovarian Carc...</td>\n",
       "      <td>[Ovarian cancer, Hyperthermic intraperitoneal ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nPre-eligibility criteri...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>18 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT05525182</td>\n",
       "      <td>Efficacy and Safety of ES16001 in Patients Wit...</td>\n",
       "      <td>Efficacy and Safety of ES16001 in Patients Wit...</td>\n",
       "      <td>This is phase II/III, randomized, parallel-gro...</td>\n",
       "      <td>After obtaining the consent and confirming eli...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Those with full unde...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>19 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT05539482</td>\n",
       "      <td>Community-Based Health Education Programs for ...</td>\n",
       "      <td>A Multicenter, Cluster-Randomized, Active-Cont...</td>\n",
       "      <td>This study evaluates the community-based healt...</td>\n",
       "      <td>This health education program is based on a Co...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[CBPR, health education, vaccination rate, ear...</td>\n",
       "      <td>For participants recruited by NGOs and compani...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>12 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05582382</td>\n",
       "      <td>Validation of Prognostic Clinical Risk Scores ...</td>\n",
       "      <td>Validation of Prognostic Clinical Risk Scores ...</td>\n",
       "      <td>Background Severe acute respiratory syndrome c...</td>\n",
       "      <td>Background:\\n\\nSince December 2019, when sever...</td>\n",
       "      <td>[COVID-19]</td>\n",
       "      <td>[hospitalization, COVID-19, clinical risk scor...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* All consecutive patie...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>16 Years</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT04910282</td>\n",
       "      <td>Impact of COVID-19 on Quality of Life of Senio...</td>\n",
       "      <td>Impact of COVID-19 on Quality of Life of Senio...</td>\n",
       "      <td>The ophthalmology clientele is vulnerable in t...</td>\n",
       "      <td>BACKGROUND AND RATIONALE\\n\\nCOVID-19 is caused...</td>\n",
       "      <td>[Covid19, Eye Diseases]</td>\n",
       "      <td>[Eye disease patients, Psychological stressors...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients diagnosed wi...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>65 Years</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  protocolSection.identificationModule.nctId  \\\n",
       "0                                NCT06684431   \n",
       "1                                NCT05735782   \n",
       "2                                NCT05505682   \n",
       "3                                NCT05787431   \n",
       "4                                NCT05808231   \n",
       "5                                NCT03842982   \n",
       "6                                NCT05525182   \n",
       "7                                NCT05539482   \n",
       "8                                NCT05582382   \n",
       "9                                NCT04910282   \n",
       "\n",
       "     protocolSection.identificationModule.briefTitle  \\\n",
       "0  Study to Evaluate Safety and Immunogenicity of...   \n",
       "1  Clinical and Biological Characterization of Po...   \n",
       "2  Impact of Project Wolbachia - Singapore on Den...   \n",
       "3  Levels of Physical Activity After SARS-CoV-2 I...   \n",
       "4  Effectiveness and Safety of Quinine Sulfate as...   \n",
       "5  Hyperthermic Intraperitoneal Chemotherapy (HIP...   \n",
       "6  Efficacy and Safety of ES16001 in Patients Wit...   \n",
       "7  Community-Based Health Education Programs for ...   \n",
       "8  Validation of Prognostic Clinical Risk Scores ...   \n",
       "9  Impact of COVID-19 on Quality of Life of Senio...   \n",
       "\n",
       "  protocolSection.identificationModule.officialTitle  \\\n",
       "0  A Phase I Study to Evaluate Safety and Immunog...   \n",
       "1  Association of Symptoms, Clinical and Biochemi...   \n",
       "2  Assessing the Efficacy of Male Wolbachia-infec...   \n",
       "3  Levels of Physical Activity After SARS-CoV-2 I...   \n",
       "4  An aDaptive, multicEnter, rAndomized, Open-Lab...   \n",
       "5  Phase III Randomized Clinical Trial Evaluating...   \n",
       "6  Efficacy and Safety of ES16001 in Patients Wit...   \n",
       "7  A Multicenter, Cluster-Randomized, Active-Cont...   \n",
       "8  Validation of Prognostic Clinical Risk Scores ...   \n",
       "9  Impact of COVID-19 on Quality of Life of Senio...   \n",
       "\n",
       "      protocolSection.descriptionModule.briefSummary  \\\n",
       "0  This First-in-human dose-escalation vaccine ph...   \n",
       "1  The goal of this observational study is to des...   \n",
       "2  The study is a cluster-randomised controlled t...   \n",
       "3  Coronavirus infection has an impact on several...   \n",
       "4  This is a multicenter, randomized, open-label,...   \n",
       "5  This is a phase III, multicenter, intervention...   \n",
       "6  This is phase II/III, randomized, parallel-gro...   \n",
       "7  This study evaluates the community-based healt...   \n",
       "8  Background Severe acute respiratory syndrome c...   \n",
       "9  The ophthalmology clientele is vulnerable in t...   \n",
       "\n",
       "  protocolSection.descriptionModule.detailedDescription  \\\n",
       "0  This First-in-human dose-escalation vaccine ph...      \n",
       "1  Two groups of cases and one group of controls ...      \n",
       "2  The study is designed as a parallel, two-arm, ...      \n",
       "3  Coronavirus identified in 2019, SARS-CoV-2 (CO...      \n",
       "4  This is an adaptive, multicenter, randomized, ...      \n",
       "5  The primary objective of this study is to asse...      \n",
       "6  After obtaining the consent and confirming eli...      \n",
       "7  This health education program is based on a Co...      \n",
       "8  Background:\\n\\nSince December 2019, when sever...      \n",
       "9  BACKGROUND AND RATIONALE\\n\\nCOVID-19 is caused...      \n",
       "\n",
       "         protocolSection.conditionsModule.conditions  \\\n",
       "0                  [Crimean Congo Hemorrhagic Fever]   \n",
       "1                                       [Long COVID]   \n",
       "2                                           [Dengue]   \n",
       "3              [COVID-19 (Coronavirus Disease 2019)]   \n",
       "4                                         [COVID-19]   \n",
       "5  [Ovary Neoplasms, Ovarian Cancer, Ovarian Carc...   \n",
       "6                                         [COVID-19]   \n",
       "7                                         [COVID-19]   \n",
       "8                                         [COVID-19]   \n",
       "9                            [Covid19, Eye Diseases]   \n",
       "\n",
       "           protocolSection.conditionsModule.keywords  \\\n",
       "0                [N-pVAX1, Phase I, Dose-escalation]   \n",
       "1  [Post-Acute COVID-19 Syndrome, Long COVID, Pos...   \n",
       "2                                                NaN   \n",
       "3  [Physical Activity, exercise, public health, P...   \n",
       "4                        [COVID-19, Quinine Sulfate]   \n",
       "5  [Ovarian cancer, Hyperthermic intraperitoneal ...   \n",
       "6                                                NaN   \n",
       "7  [CBPR, health education, vaccination rate, ear...   \n",
       "8  [hospitalization, COVID-19, clinical risk scor...   \n",
       "9  [Eye disease patients, Psychological stressors...   \n",
       "\n",
       "  protocolSection.eligibilityModule.eligibilityCriteria  \\\n",
       "0  Inclusion Criteria:\\n\\n1. Men and women betwee...      \n",
       "1  Two groups of cases and one group of controls ...      \n",
       "2  Inclusion criteria:\\n\\n* Dengue-suspected pati...      \n",
       "3  Inclusion Criteria:\\n\\nCOVID-19 recovered indi...      \n",
       "4  Inclusion Criteria:\\n\\n* Male and female patie...      \n",
       "5  Inclusion Criteria:\\n\\nPre-eligibility criteri...      \n",
       "6  Inclusion Criteria:\\n\\n1. Those with full unde...      \n",
       "7  For participants recruited by NGOs and compani...      \n",
       "8  Inclusion Criteria:\\n\\n* All consecutive patie...      \n",
       "9  Inclusion Criteria:\\n\\n* Patients diagnosed wi...      \n",
       "\n",
       "  protocolSection.eligibilityModule.sex  \\\n",
       "0                                   ALL   \n",
       "1                                   ALL   \n",
       "2                                   ALL   \n",
       "3                                   ALL   \n",
       "4                                   ALL   \n",
       "5                                FEMALE   \n",
       "6                                   ALL   \n",
       "7                                   ALL   \n",
       "8                                   ALL   \n",
       "9                                   ALL   \n",
       "\n",
       "  protocolSection.eligibilityModule.minimumAge  \n",
       "0                                     18 Years  \n",
       "1                                     18 Years  \n",
       "2                                          NaN  \n",
       "3                                     18 Years  \n",
       "4                                     18 Years  \n",
       "5                                     18 Years  \n",
       "6                                     19 Years  \n",
       "7                                     12 Years  \n",
       "8                                     16 Years  \n",
       "9                                     65 Years  "
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#take the previosu json response and get the nctID, Official Title, Eligibility Criteria, Disease Characteristics\n",
    "clinical_df = clinical_df[['protocolSection.identificationModule.nctId', 'protocolSection.identificationModule.briefTitle', 'protocolSection.identificationModule.officialTitle', 'protocolSection.descriptionModule.briefSummary', 'protocolSection.descriptionModule.detailedDescription', 'protocolSection.conditionsModule.conditions', 'protocolSection.conditionsModule.keywords', 'protocolSection.eligibilityModule.eligibilityCriteria', 'protocolSection.eligibilityModule.sex', 'protocolSection.eligibilityModule.minimumAge']]\n",
    "clinical_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT ID: NCT06684431, Official Title: A Phase I Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever, Sex: ALL, Minimum Age: 18 Years\n",
      "\n",
      "NCT ID: NCT05735782, Official Title: Association of Symptoms, Clinical and Biochemical Characteristics in Post COVID-19 Syndrome: a Case-control Study, Sex: ALL, Minimum Age: 18 Years\n",
      "\n",
      "NCT ID: NCT05505682, Official Title: Assessing the Efficacy of Male Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Singapore: a Cluster Randomized Controlled Trial, Sex: ALL, Minimum Age: nan\n",
      "\n",
      "NCT ID: NCT05787431, Official Title: Levels of Physical Activity After SARS-CoV-2 Infection in Greek Adults: the Role of Pre-illness Vaccination and the Number of Reinfections., Sex: ALL, Minimum Age: 18 Years\n",
      "\n",
      "NCT ID: NCT05808231, Official Title: An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults, Sex: ALL, Minimum Age: 18 Years\n",
      "\n",
      "NCT ID: NCT03842982, Official Title: Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS), Sex: FEMALE, Minimum Age: 18 Years\n",
      "\n",
      "NCT ID: NCT05525182, Official Title: Efficacy and Safety of ES16001 in Patients With COVID-19: a Phase II/III, Multinational, Randomized, Parallel-group, Double-blind, Placebo-controlled Study, Sex: ALL, Minimum Age: 19 Years\n",
      "\n",
      "NCT ID: NCT05539482, Official Title: A Multicenter, Cluster-Randomized, Active-Controlled, Single-Blind Trial of Community-Based Health Education Programs for the Early Detection of, and Vaccination Against, COVID-19 and the Adoption of Self-Protective Measures of Hong Kong Residents, Sex: ALL, Minimum Age: 12 Years\n",
      "\n",
      "NCT ID: NCT05582382, Official Title: Validation of Prognostic Clinical Risk Scores in Predicting Outcomes for Patients Diagnosed With COVID-19 During Initial Triage Assessment, Sex: ALL, Minimum Age: 16 Years\n",
      "\n",
      "NCT ID: NCT04910282, Official Title: Impact of COVID-19 on Quality of Life of Seniors With Eye Disease and Implementations to Improve Wellness, Sex: ALL, Minimum Age: 65 Years\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Initialize an empty string to store the combined output\n",
    "trial_list = \"\"\n",
    "\n",
    "# Loop through each row in the DataFrame and concatenate the information\n",
    "for index, row in clinical_df.iterrows():\n",
    "    # Concatenate relevant columns into a single string for each row\n",
    "    trial_info = (\n",
    "        f\"NCT ID: {row['protocolSection.identificationModule.nctId']}, \"\n",
    "        #f\"Brief Title: {row['protocolSection.identificationModule.briefTitle']}, \"\n",
    "        f\"Official Title: {row['protocolSection.identificationModule.officialTitle']}, \"\n",
    "        #f\"Brief Summary: {row['protocolSection.descriptionModule.briefSummary']}, \"\n",
    "        #f\"Detailed Description: {row['protocolSection.descriptionModule.detailedDescription']}, \"\n",
    "        #f\"Conditions: {', '.join(row['protocolSection.conditionsModule.conditions'])}, \"\n",
    "        #f\"Keywords: {', '.join(row['protocolSection.conditionsModule.keywords'])}, \"\n",
    "        #f\"Eligibility Criteria: {row['protocolSection.eligibilityModule.eligibilityCriteria']}, \"\n",
    "        f\"Sex: {row['protocolSection.eligibilityModule.sex']}, \"\n",
    "        f\"Minimum Age: {row['protocolSection.eligibilityModule.minimumAge']}\\n\\n\"\n",
    "    )\n",
    "    \n",
    "    # Append this patient string to the combined string\n",
    "    trial_list += trial_info\n",
    "\n",
    "# Print the combined string\n",
    "print(trial_list)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [],
   "source": [
    "import openai "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Response 1: Patient Alejandro916, a male, was diagnosed with Acute viral pharyngitis at the age of 13 in 2014. In 2018, at age 17, he was diagnosed with Viral sinusitis. In 2020, at age 19, Alejandro916 was diagnosed with a series of medical conditions beginning with Acute bacterial sinusitis, followed by a sputum finding, fever, loss of taste, a suspicion of COVID-19 before finally being diagnosed with COVID-19.\n",
      "\n",
      "Response 2: 1) NCT06684431 - This trial is a phase I study evaluating the safety and immunogenicity of the DNA vaccine N-pVAX1 against Crimean Congo Hemorrhagic Fever. Open to all individuals aged 18 and above.\n",
      "\n",
      "2) NCT05735782 - It is a case-control study investigating the association of symptoms, clinical, and biochemical characteristics in post COVID-19 syndrome. All individuals 18 years and older are eligible.\n",
      "\n",
      "3) NCT05505682 - The efficacy of male Wolbachia-infected mosquito deployments in reducing the incidence of dengue in Singapore is being assessed in this cluster randomized controlled trial. The study does not specify a minimum age limit, hence it's open to all age groups.\n",
      "\n",
      "4) NCT05787431 - The study is evaluating levels of physical activity after SARS-CoV-2 infection in Greek adults, taking into account pre-illness vaccination and the number of reinfections. Individuals of all genders aged 18 and above will be considered.\n",
      "\n",
      "5) NCT05808231 - This randomized, open-label, controlled trial is assessing the effectiveness and safety of quinine sulfate for treating COVID-19 in hospitalized adults. Individuals 18 years old and older of any sex are eligible.\n",
      "\n",
      "6) NCT03842982 - It is a Phase III clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer patients under two different settings. It's only open to female participants 18 years and older.\n",
      "\n",
      "7) NCT05525182 - This phase II/III study investigates the efficacy and safety of ES16001 in patients with COVID-19. All individuals aged 19 and above may participate.\n",
      "\n",
      "8) NCT05539482 - A trial of community-based health education programs for early detection of, and vaccination against, COVID-19, open to everyone aged 12 and above.\n",
      "\n",
      "9) NCT05582382 - The study is validating prognostic clinical risk scores in predicting outcomes for patients diagnosed with COVID-19 during initial triage assessment. All interested individuals aged 16 and older are welcome to participate.\n",
      "\n",
      "10) NCT04910282 - This study assesses the impact of COVID-19 on the quality of life of seniors with eye disease and implementations to improve wellness. It's open to all individual aged 65 and above.\n",
      "  \n",
      "A good candidate for these trials would be someone who meets the minimum age requirements, and the gender requirements where specified. Other specific conditions or statuses of the potential participants are also factors to consider such as being diagnosed with Covid-19, having ovarian cancer, or being seniors with eye disease.\n",
      "\n",
      "Response 3: - **NCT ID**: NCT06684431\n",
      "- **Match Score**: 0%\n",
      "- **Rationale**: This patient is not eligible for this trial as the study is aimed at evaluating a vaccine against Crimean Congo Hemorrhagic Fever, and the patient was not diagnosed with this condition.\n",
      "\n",
      "- **NCT ID**: NCT05735782\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: The patient is a confirmed case of COVID-19 and given the minimum age requirement (18 years) which he meets, the patient is perfectly eligible for a post-COVID-19 syndrome study.\n",
      "\n",
      "- **NCT ID**: NCT05505682\n",
      "- **Match Score**: 0%\n",
      "- **Rationale**: The patient is not eligible for this trial as the study is aimed at reducing Dengue incidence, and the patient has no reported case of Dengue.\n",
      "\n",
      "- **NCT ID**: NCT05787431\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: The patient is eligible for this trial as it involves individuals who had contracted the SARS-CoV-2 virus, and the patient had a confirmed case of COVID-19 when he was 19 years old.\n",
      "\n",
      "- **NCT ID**: NCT05808231\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: The patient is eligible for this trial as it involves hospitalized adults with COVID-19, something Alejandro916 has experienced. \n",
      "\n",
      "- **NCT ID**: NCT03842982\n",
      "- **Match Score**: 0%\n",
      "- **Rationale**: The patient is not eligible for this trial as this study only involves female patients diagnosed with Ovarian Cancer, which he hasn't been.\n",
      "\n",
      "- **NCT ID**: NCT05525182\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: Given Alejandro916's confirmed case of COVID-19 at the age of 19, he is perfectly eligible for this multinational study on the efficacy and safety of ES16001 in Patients With COVID-19.\n",
      "\n",
      "- **NCT ID**: NCT05539482\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: Alejandro916 is eligible for this trial as it involves health education programs for the early detection of, and vaccination against, COVID-19 which is plausible given his past experience with the virus.\n",
      "\n",
      "- **NCT ID**: NCT05582382\n",
      "- **Match Score**: 100%\n",
      "- **Rationale**: Alejandro916 is eligible for this trial as it is about predicting outcomes for Patients diagnosed With COVID-19 During Initial Triage Assessment, something he went through when he was just 19 years old.\n",
      "\n",
      "- **NCT ID**: NCT04910282\n",
      "- **Match Score**: 0%\n",
      "- **Rationale**: The patient does not qualify for this trial as it requires a minimum age of 65 years and focuses on the impact of COVID-19 on quality of life of seniors with eye disease, conditions that do not match the patient's profile.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Set your API key\n",
    "openai.api_key = \"\"\n",
    "\n",
    "# List of prompts to query the LLM\n",
    "prompts = [\n",
    "    f\"Summarize this patient's medical history: '{patient_summary}'\", \n",
    "    f\"I have provided a list of clinical trials with eligibility and inclusion information. Please summarize trials and identify the characteristics of a patient that would be a good candidate for these trials '{trial_list}'\", \n",
    "    f\"\"\"\n",
    "Please evaluate whether the patient described in \"{patient_summary}\" would be eligible for each clinical trial listed in {trial_list}. For each trial, provide:\n",
    "1. A **Match Score** from 0% to 100%.\n",
    "2. A **Rationale** explaining why the patient is or isnâ€™t eligible for the trial.\n",
    "\n",
    "Ensure that each trial's response is clearly organized with the following labels:\n",
    "- **NCT ID**: [The trial's NCT ID]\n",
    "- **Match Score**: [The eligibility score, e.g., 0%, 25%, 50%, 75%, 100%]\n",
    "- **Rationale**: [A brief explanation of why the patient is or isn't eligible for this trial]\n",
    "\"\"\"\n",
    "]\n",
    "\n",
    "# Store responses\n",
    "responses = []\n",
    "\n",
    "# Query the chat model for each prompt\n",
    "for prompt in prompts:\n",
    "    response = openai.ChatCompletion.create(\n",
    "        model=\"gpt-4\",  # Specify your chat model\n",
    "        messages=[\n",
    "            {\"role\": \"system\", \"content\": \"You are a clinical research assistant.\"},\n",
    "            {\"role\": \"user\", \"content\": prompt}\n",
    "        ],\n",
    "        max_tokens=4000\n",
    "    )\n",
    "    responses.append(response.choices[0].message[\"content\"].strip())  # Save the response\n",
    "\n",
    "# Print all responses\n",
    "for i, (prompt, response) in enumerate(zip(prompts, responses), 1):\n",
    "    #print(f\"Prompt {i}: {prompt}\")\n",
    "    print(f\"Response {i}: {response}\\n\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
